Evidence-based medicine: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Gareth Leng
(resolvijng (hopefully) last of duplicate reference definitions)
 
(197 intermediate revisions by 12 users not shown)
Line 1: Line 1:
{{Subpages}}
{{Subpages}}{{TOC|right}}  
'''Evidence-based medicine''' is ''"the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients."''.<ref name="pmid8555924">{{cite journal |author=Sackett DL ''et al.''|title=Evidence based medicine: what it is and what it isn't |journal=BMJ |volume=312 |pages=71–2 |year=1996 |pmid=8555924 |doi=}}</ref> Alternative definitions are "''the process of systematically finding, appraising, and using contemporaneous research findings as the basis for clinical decisions''"<ref name="pmid1404801">{{cite journal |author= |title=Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group|author=Evidence-Based Medicine Working Group |journal=JAMA |volume=268 |pages=2420–5 |year=1992 |pmid=1404801 |doi=}}</ref> or "''evidence-based medicine (EBM) requires the integration of the best research evidence with our clinical expertise and our patient's unique values and circumstances''."<ref name="isbn0-443-07444-5">{{cite book |author=Glasziou, Paul; Strauss, Sharon Y. |title=Evidence-based medicine: how to practice and teach EBM |publisher=Elsevier/Churchill Livingstone |location= |year=2005 |pages= |isbn=0-443-07444-5 |oclc= |doi=}}</ref>  Better known as EBM, evidence based medicine emerged in the early 1990's to help healthcare providers and policy makers evaluate the efficacy of different treatments.
'''[[Evidence]]-based [[medicine]]''' is ''"the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients."''<ref name="pmid8555924">{{cite journal |author=Sackett DL ''et al.''|title=Evidence based medicine: what it is and what it isn't |journal=BMJ |volume=312 |pages=71–2 |year=1996 |pmid=8555924 |doi=}}</ref> Alternative definitions are "''the process of systematically finding, appraising, and using contemporaneous research findings as the basis for clinical decisions''"<ref name="pmid1404801">{{cite journal |author= |title=Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group|author=Evidence-Based Medicine Working Group |journal=JAMA |volume=268 |pages=2420–5 |year=1992 |pmid=1404801 |doi=}}</ref> or "''evidence-based medicine (EBM) requires the integration of the best research evidence with our clinical expertise and our patient's unique values and circumstances''."<ref name="isbn0-443-07444-5">{{cite book |author=Glasziou, Paul; Strauss, Sharon Y. |title=Evidence-based medicine: how to practice and teach EBM |publisher=Elsevier/Churchill Livingstone |location= |year=2005 |pages= |isbn=0-443-07444-5 |oclc= |doi=}}</ref>  Better known as EBM, evidence based medicine has roots in clinical [[epidemiology]] and the [[scientific method]], and emerged in the early 1990's in response to discoveries about variations and deficiencies<ref name="pmid18361259">{{cite journal |author=Thier SL, Yu-Isenberg KS, Leas BF ''et al'' |title=In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines |journal=Manag Care |volume=17  |pages=48-52, 55-7 |year=2008 |pmid=18361259 |doi= |issn=}}</ref> in medical care to help healthcare providers and policy makers evaluate the efficacy of different treatments.


Evidence-based practice is not restricted to medicine; dentistry, nursing and other allied health science are adopting "evidence-based medicine" as well as [[alternative medicine|alternative medical]] approaches, such as [[acupuncture]]<ref name="pmid-17577006">{{cite journal |author=Manheimer E ''et al.'' |title=Meta-analysis: acupuncture for osteoarthritis of the knee |journal=Ann Intern Med |volume=146  |pages=868–77 |year=2007 |pmid=17577006 |doi= |issn=}}</ref><ref name="pmid-15998750">{{cite journal |author=Assefi NP ''et al.'' |title=A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia |journal=Ann Intern Med |volume=143  |pages=10–9 |year=2005 |pmid=15998750 |doi= |issn=}}</ref>.  ''Evidence-Based Health Care'' or ''evidence-based practice'' extends the concept of EBM to all health professions, including management<ref name="pmid-15647226">{{cite journal |author=Clancy CM, Cronin K |title=Evidence-based decision making: global evidence, local decisions |journal=Health affairs (Project Hope) |volume=24  |pages=151–62 |year=2005 |pmid=15647226 |doi=10.1377/hlthaff.24.1.151}}</ref><ref name="pmid-15647225">{{cite journal |author=Shojania KG, Grimshaw JM |title=Evidence-based quality improvement: the state of the science |journal=Health affairs (Project Hope) |volume=24  |pages=138–50 |year=2005 |pmid=15647225 |doi=10.1377/hlthaff.24.1.138}}</ref> and policy<ref name="pmid-16835176">{{cite journal |author=Fielding JE, Briss PA |title=Promoting evidence-based public health policy: can we have better evidence and more action? |journal=Health affairs (Project Hope) |volume=25  |pages=969–78 |year=2006 |pmid=16835176 |doi=10.1377/hlthaff.25.4.969}}</ref><ref name="pmid-17978383">{{cite journal |author=Foote SB, Town RJ |title=Implementing evidence-based medicine through medicare coverage decisions |journal=Health affairs (Project Hope) |volume=26 |issue=6 |pages=1634–42 |year=2007 |pmid=17978383 |doi=10.1377/hlthaff.26.6.1634}}</ref><ref name="pmid-15647221">{{cite journal |author=Fox DM |title=Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions |journal=Health affairs (Project Hope) |volume=24  |pages=114–22 |year=2005 |pmid=15647221 |doi=10.1377/hlthaff.24.1.114}}</ref>.
Evidence-based practice is not restricted to medicine: [[dentistry]], [[nursing]] and other allied [[health science]] are adopting "evidence-based medicine" as well as [[alternative medicine|alternative medical]] approaches, such as [[acupuncture]]<ref name="pmid-17577006">{{cite journal |author=Manheimer E ''et al.'' |title=Meta-analysis: acupuncture for osteoarthritis of the knee |journal=Ann Intern Med |volume=146  |pages=868–77 |year=2007 |pmid=17577006 |doi= |issn=}}</ref><ref name="pmid-15998750">{{cite journal |author=Assefi NP ''et al.'' |title=A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia |journal=Ann Intern Med |volume=143  |pages=10–9 |year=2005 |pmid=15998750 |doi= |issn=}}</ref>.  ''Evidence-Based Health Care'' or ''evidence-based practice'' extends the concept of EBM to all health professions, including management<ref name="pmid-15647226">{{cite journal |author=Clancy CM, Cronin K |title=Evidence-based decision making: global evidence, local decisions |journal=Health Affairs (Project Hope) |volume=24  |pages=151–62 |year=2005 |pmid=15647226 |doi=10.1377/hlthaff.24.1.151}}</ref><ref name="pmid-15647225">{{cite journal |author=Shojania KG, Grimshaw JM |title=Evidence-based quality improvement: the state of the science |journal=Health Affairs (Project Hope) |volume=24  |pages=138–50 |year=2005 |pmid=15647225 |doi=10.1377/hlthaff.24.1.138}}</ref> and policy<ref name="pmid-16835176">{{cite journal |author=Fielding JE, Briss PA |title=Promoting evidence-based public health policy: can we have better evidence and more action? |journal=Health Affairs (Project Hope) |volume=25  |pages=969–78 |year=2006 |pmid=16835176 |doi=10.1377/hlthaff.25.4.969}}</ref><ref name="pmid-17978383">{{cite journal |author=Foote SB, Town RJ |title=Implementing evidence-based medicine through medicare coverage decisions |journal=Health Affairs (Project Hope) |volume=26 |issue=6 |pages=1634–42 |year=2007 |pmid=17978383 |doi=10.1377/hlthaff.26.6.1634}}</ref><ref name="pmid-15647221">{{cite journal |author=Fox DM |title=Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions |journal=Health Affairs (Project Hope) |volume=24  |pages=114–22 |year=2005 |pmid=15647221 |doi=10.1377/hlthaff.24.1.114}}</ref>.


Two types of evidence-based medicine have been proposed.<ref name="pmid15647211">{{cite journal |author=Eddy DM |title=Evidence-based medicine: a unified approach |journal=Health affairs (Project Hope) |volume=24 |pages=9-17 |year=2005 |pmid=15647211 |doi=10.1377/hlthaff.24.1.9}}</ref> ''Evidence-based guidelines''  is EBM at the ''organizational or institutional'' level, and involves producing guidelines, policy, and regulations. ''[[Evidence-based individual decision making]]'' is EBM as practiced by an individual [[health care provider]] when treating an individual patient.
==Classification==
Two types of evidence-based medicine have been proposed:<ref name="pmid15647211">{{cite journal |author=Eddy DM |title=Evidence-based medicine: a unified approach |journal=Health Affairs (Project Hope) |volume=24 |pages=9-17 |year=2005 |pmid=15647211 |doi=10.1377/hlthaff.24.1.9}}</ref>


==Why do we need evidence-based medicine?==
* ''Evidence-based guidelines'', EBM at the ''organizational or institutional'' level, which involves producing [[clinical practice guideline]]s, policy, and regulations;
It is easy to assume that physicians always use scientific evidence conscientiously and judiciously in treating patients. In fact, most of the specific practices of physicians and surgeons are based on traditional techniques learned from their mentors in the care of patients during training. Additional modifications come from personal clinical experience, from information in the medical literature and continuing education courses. Although these practices almost always have a rational basis in biology, the actual efficacy of treatments is rarely tested by experimental trials in people. Further, even when the results of experimental trials or other evidence have been reported, there is a lag time between the acceptance of changes to medical practice and establishing them as routine in clinical care. EBM seeks to address these issues by promoting practices that have been shown to have validity using the [[scientific method]].


==Steps in evidence-based medicine==
*''[[Evidence-based individual decision making]]'', EBM as practiced by an individual [[health care provider]] when treating an individual patient. There is concern that evidence-based medicine focuses excessively on the physician-patient dyad and as a result miss many opportunities to improve healthcare.<ref name="pmid15647211"/>
 
==Justification==
Part of the justification for EBM is the unreliability about making clinical decisions using heuristics.<ref name="pmid19231086">{{cite journal| author=Aberegg SK, O'Brien JM| title=The normalization heuristic: an untested hypothesis that may misguide medical decisions. | journal=Med Hypotheses | year= 2009 | volume= 72 | issue= 6 | pages= 745-8 | pmid=19231086
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19231086 | doi=10.1016/j.mehy.2008.10.030 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref><ref name="pmid7503478">{{cite journal| author=McDonald CJ| title=Medical heuristics: the silent adjudicators of clinical practice. | journal=Ann Intern Med | year= 1996 | volume= 124 | issue= 1 Pt 1 | pages= 56-62 | pmid=7503478
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=7503478 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
 
==Steps in EBM==
:''See also [[Teaching evidence-based medicine]]''
{|align="right" cellpadding="10" style="background-color:#FFFFCC; width:50%; border: 1px solid #aaa; margin:20px; font-size: 92%;"
|''The 5 S search strategy''<ref name="pmid17080967">{{cite journal |author=Haynes RB |title=Of studies, syntheses, synopses, summaries, and systems: the "5S" evolution of information services for evidence-based health care decisions |journal=ACP J Club |volume=145 |pages=A8 |year=2006 |pmid=17080967 |doi=|url=http://www.acpjc.org/Content/145/3/issue/ACPJC-2006-145-3-A08.htm}}</ref>
 
'''Studies''': original research studies that can be found using search engines like PubMed.
 
'''Synthesis''': systematic reviews or Cochrane Reviews.
 
'''Synopses''': in EBM journals, ACP Journal club etc. give brief descriptions of original articles and reviews as they appear .
 
'''Summaries''':  in EBM textbooks integrate the best available evidence from syntheses to give evidence-based management options for a health problem.
 
'''Systems''': e.g. computerized decision support systems that link individual patient characteristics to relevant evidence.
|}
===Ask===
===Ask===
"'''Ask'''" - Formulate a well-structured clinical question.
To "'''ask'''" and formulate a well-structured clinical question, i.e. one that is directly relevant to the identified problem, and which is constructed in a way that facilitates searching for an answer. The question should have four 'PICO' elements<ref name="pmid7582737">{{cite journal| author=Richardson WS, Wilson MC, Nishikawa J, Hayward RS| title=The well-built clinical question: a key to evidence-based decisions. | journal=ACP J Club | year= 1995 Nov-Dec | volume= 123 | issue= 3 | pages= A12-3 | pmid=7582737
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=7582737 }} </ref><ref name="pmid17238363">{{cite journal |author=Huang X, Lin J, Demner-Fushman D |title=Evaluation of PICO as a knowledge representation for clinical questions |journal=AMIA Annu Symp Proc |volume= |issue= |pages=359–63 |year=2006 |pmid=17238363 |pmc=1839740 |doi= |url= |issn=}}</ref>: the patient or problem ('''P'''); the medical intervention or exposure (e.g., a cause for a disease) ('''I'''); the comparison intervention or exposure ('''C'''); and the clinical outcomes ('''O'''). The better focused the question is, the more relevant and specific the search for evidence will be.<ref name="pmid17573961">{{cite journal |author=Schardt C, Adams MB, Owens T, Keitz S, Fontelo P |title=Utilization of the PICO framework to improve searching PubMed for clinical questions |journal=BMC Med Inform Decis Mak |volume=7 |issue= |pages=16 |year=2007 |pmid=17573961 |pmc=1904193 |doi=10.1186/1472-6947-7-16 |url=http://www.biomedcentral.com/1472-6947/7/16 |issn=}}</ref>


===Acquisition of evidence===
===Acquisition of evidence===
The ability to "'''acquire'''" evidence in a timely manner may improve healthcare.<ref name="pmid17971885">{{cite journal |author=Banks DE ''et al.'' |title=Decreased hospital length of stay associated with presentation of cases at morning report with librarian support |journal=Journal of the Medical Library Association : JMLA |volume=95 |pages=381–7 |year=2007 |pmid=17971885 |doi=10.3163/1536-5050.95.4.381 |issn=}}</ref> Unfortunately, doctors may be led astray when acquiring information if they do not systematically review all available evidence, because individual trials may be flawed or their outcomes may not be fully representative.<ref name="pmid16929042">{{cite journal |author=McKibbon KA, Fridsma DB |title=Effectiveness of clinician-selected electronic information resources for answering primary care physicians' information needs |journal=Journal of the American Medical Informatics Association : JAMIA |volume=13 |pages=653–9 |year=2006 |pmid=16929042 |doi=10.1197/jamia.M2087}}</ref>
 
One proposed structure for a comprehensive evidence search is the 5S search strategy,<ref name="pmid17080967">{{cite journal |author=Haynes RB |title=Of studies, syntheses, synopses, summaries, and systems: the "5S" evolution of information services for evidence-based health care decisions |journal=ACP J Club |volume=145 |pages=A8 |year=2006 |pmid=17080967 |doi=}}</ref> which starts with the search of "summaries" (textbooks). <ref name="pmid17082828">{{cite journal |author=Patel MR ''et al.'' |title=Randomized trial for answers to clinical questions: evaluating a pre-appraised versus a [[MEDLINE]] search protocol |journal= JMLA |volume=94 |pages=382–7 |year=2006 |pmid=17082828 |doi=}}</ref>
{| class="wikitable" align="right"
|+ Acquisition is difficult due to instability of medical knowledge<ref name="pmid16014596">{{cite journal| author=Ioannidis JP| title=Contradicted and initially stronger effects in highly cited clinical research. | journal=JAMA | year= 2005 | volume= 294 | issue= 2 | pages= 218-28 | pmid=16014596
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16014596 | doi=10.1001/jama.294.2.218 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref><ref name="pmid12069563">{{cite journal| author=Poynard T, Munteanu M, Ratziu V, Benhamou Y, Di Martino V, Taieb J et al.| title=Truth survival in clinical research: an evidence-based requiem? | journal=Ann Intern Med | year= 2002 | volume= 136 | issue= 12 | pages= 888-95 | pmid=12069563
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12069563 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref><ref name="pmid9413475">{{cite journal| author=Hall JC, Platell C| title=Half-life of truth in surgical literature. | journal=Lancet | year= 1997 | volume= 350 | issue= 9093 | pages= 1752 | pmid=9413475
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9413475 | doi=10.1016/S0140-6736(05)63577-5 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref><ref name="pmid17638714">{{cite journal| author=Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D| title=How quickly do systematic reviews go out of date? A survival analysis. | journal=Ann Intern Med | year= 2007 | volume= 147 | issue= 4 | pages= 224-33 | pmid=17638714
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17638714 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref><ref name="pmid11572738">{{cite journal| author=Shekelle PG, Ortiz E, Rhodes S, Morton SC, Eccles MP, Grimshaw JM et al.| title=Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? | journal=JAMA | year= 2001 | volume= 286 | issue= 12 | pages= 1461-7 | pmid=11572738
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11572738 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref><ref name="pmid11980521">{{cite journal| author=Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH| title=Timing of new black box warnings and withdrawals for prescription medications. | journal=JAMA | year= 2002 | volume= 287 | issue= 17 | pages= 2215-20 | pmid=11980521
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11980521 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
! Type of publication!! Durability
|-
| style="text-align:center;font-weight:bold;" colspan="2"|Primary publications
|-
| Highly cited studies major [[scientific journal]]s<ref name="pmid16014596"/>|| The results from one-third are refuted or attenuated within 15 years.
|-
| Original studies in hepatology<ref name="pmid12069563"/>|| Half-life of truth was 45 years
|-
| Original studies in surgery<ref name="pmid9413475"/>||  Half-life of truth was 45 years
|-
| style="text-align:center;font-weight:bold;" colspan="2"|Secondary publications
|-
| [[Systematic review]]s<ref name="pmid17638714"/>|| Median survival is 5.5 years.<br/>7% may out of date when published<br/> 23% may be out of date within 2 years
|-
| [[Clinical practice guideline|Practice guidelines]] by the [[Agency for Healthcare Research and Quality|AHRQ]]<ref name="pmid11572738"/>|| Half-life of truth was 5.8 years
|-
| [[Food and Drug Administration]] New Drug Approvals<ref name="pmid11980521"/>|| 8% acquire a new black box warning. Half occur within 7 years
|-
| [[Food and Drug Administration]] New Drug Approvals<ref name="pmid11980521"/>|| 3% withdrawn. Half occur within 2 years
|}
 
The ability to "'''acquire'''" evidence, also called [[information retrieval]], in a timely manner may improve healthcare.<ref name="pmid17971885">{{cite journal |author=Banks DE ''et al.'' |title=Decreased hospital length of stay associated with presentation of cases at morning report with librarian support |journal=JMLA |volume=95 |pages=381–7 |year=2007 |pmid=17971885 |doi=10.3163/1536-5050.95.4.381 |issn=}}</ref><ref name="pmid15109337">{{cite journal |author=Lucas BP, Evans AT, Reilly BM, ''et al'' |title=The impact of evidence on physicians' inpatient treatment decisions |journal=J Gen Intern Med |volume=19 |issue=5 Pt 1 |pages=402–9 |year=2004 |pmid=15109337 |doi=10.1111/j.1525-1497.2004.30306.x |issn=}}</ref> Unfortunately, doctors may be led astray when acquiring information because of difficulties in selecting best articles<ref name="pmid15618105">{{cite journal |author=Rosenbloom ST, Giuse NB, Jerome RN, Blackford JU |title=Providing evidence-based answers to complex clinical questions: evaluating the consistency of article selection |journal=Acad Med |volume=80 |issue=1 |pages=109–14 |year=2005 |month=January |pmid=15618105 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1040-2446&volume=80&issue=1&spage=109 |issn=}}</ref>, or because individual trials may be flawed or their outcomes may not be fully representative.<ref name="pmid16929042">{{cite journal |author=McKibbon KA, Fridsma DB |title=Effectiveness of clinician-selected electronic information resources for answering primary care physicians' information needs |journal=JAMIA |volume=13 |pages=653–9 |year=2006 |pmid=16929042 |doi=10.1197/jamia.M2087}}</ref>
 
Research conflicts on the ability of end-users of MEDLINE. One study found that users were almost as likely to misinterpret articles found as correctly interpret them.<ref name="pmid16929042"/> A second study that was in vitro found that searching for evidence was helpful.<ref name="pmid15684126">{{cite journal |author=Westbrook JI, Coiera EW, Gosling AS |title=Do online information retrieval systems help experienced clinicians answer clinical questions? |journal=J Am Med Inform Assoc |volume=12 |issue=3 |pages=315–21 |year=2005 |pmid=15684126 |doi=10.1197/jamia.M1717 |url=http://www.jamia.org/cgi/pmidlookup?view=long&pmid=15684126 |issn=}}</ref>
 
One proposed structure for a comprehensive evidence search is the 5S search strategy,<ref name="pmid17080967"/> and 6S<ref name="pmid19755349">{{cite journal| author=DiCenso A, Bayley L, Haynes RB| title=ACP Journal Club. Editorial: Accessing preappraised evidence: fine-tuning the 5S model into a 6S model. | journal=Ann Intern Med | year= 2009 | volume= 151 | issue= 6 | pages= JC3-2, JC3-3 | pmid=19755349
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19755349 }} [http://www.acpjc.org/Content/151/3/issue/ACPJC-2009-151-3-002.htm Full text from www.acpjc.org]<!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> which starts with the search of "summaries" (textbooks). <ref name="pmid17082828">{{cite journal |author=Patel MR ''et al.'' |title=Randomized trial for answers to clinical questions: evaluating a pre-appraised versus a [[MEDLINE]] search protocol |journal= JMLA |volume=94 |pages=382–7 |year=2006 |pmid=17082828 |doi=}}</ref>


===Appraisal of evidence===
===Appraisal of evidence===
<!-- Start of USPSTF text box -->
{|align="right" cellpadding="10" style="background-color:#FFFFCC; width:50%; border: 1px solid #aaa; margin:20px; font-size: 92%;"
{|align="right" cellpadding="10" style="background-color:#FFFFCC; width:50%; border: 1px solid #aaa; margin:20px; font-size: 92%;"
|
|
The U.S. Preventive Services Task Force <ref>U.S. Preventive Services Task Force Ratings: [[http://www.ahrq.gov/clinic/3rduspstf/ratings.htm  Strength of Recommendations and Quality of Evidence. Guide to Clinical Preventive Services], Third Edition: Periodic Updates, 2000-2003. Hosted by Agency for Healthcare Research and Quality, Rockville, MD.</ref> grades its recommendations for treatments according to the strength of the evidence and the expected overall benefit (benefits minus harms). Its five grades are:
The [[U.S. Preventive Services Task Force]] (USPSTF) <ref>U.S. Preventive Services Task Force Ratings: [[http://www.ahrq.gov/clinic/3rduspstf/ratings.htm  Strength of Recommendations and Quality of Evidence. Guide to Clinical Preventive Services], Third Edition: Periodic Updates, 2000-2003. Hosted by Agency for Healthcare Research and Quality, Rockville, MD.</ref> grades its recommendations for treatments according to the strength of the evidence and the expected overall benefit (benefits minus harms). Its grades are:


A.— There is good evidence that the treatment improves important health outcomes, and benefits substantially outweigh harms.
A.— Good evidence that the treatment improves health outcomes, and benefits substantially outweigh harms.


B.— There is fair evidence that the treatment improves important health outcomes and that benefits outweigh harms.
B.— Fair evidence that the treatment improves health outcomes and that benefits outweigh harms.


C.— There is fair evidence that the treatment can improve health outcomes but the balance of benefits and harms is too close to justify a general recommendation.
C.— Fair evidence that the treatment can improve health outcomes but the balance of benefits and harms is too close to justify a general recommendation.


D.— Recommendation against routinely providing the treatment to asymptomatic patients. There is fair evidence that [the service] is ineffective or that harms outweigh benefits.
D.— Recommendation against routinely providing the treatment to asymptomatic patients. There is fair evidence that [the service] is ineffective or that harms outweigh benefits.
Line 32: Line 89:
I.— The evidence is insufficient to recommend for or against routinely providing [the service]. Evidence that the treatment is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined.
I.— The evidence is insufficient to recommend for or against routinely providing [the service]. Evidence that the treatment is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined.


The USPSTF also grades the quality of the overall evidence for a service as good, fair or poor:
The USPSTF also grades the quality of the overall evidence as good, fair or poor:


''Good'': Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.
''Good'': Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health.


''Fair'': Evidence is sufficient to determine effects on health outcomes, but its strength is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes.
''Fair'': Evidence is sufficient to determine effects on health outcomes, but its strength is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes.


''Poor'': Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.
''Poor'': Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.
|}To "'''Appraise'''" the quality of the evidence found is very important, as one third of the results of even the most visible medical research is eventually either attenuated or refuted.<ref name="pmid16014596">{{cite journal |author=Ioannidis JP |title=Contradicted and initially stronger effects in highly cited clinical research |journal=JAMA |volume=294  |pages=218–28 |year=2005 |pmid=16014596 |doi=10.1001/jama.294.2.218}}</ref> There are many reasons for this<ref name="pmid9546568">{{cite journal |author=Ioannidis JP ''et al.''|title=Issues in comparisons between meta-analyses and large trials |journal=JAMA |volume=279 |pages=1089–93 |year=1998 |pmid=9546568 |doi=}}</ref>; two important reasons are publication bias<ref name="pmid1727960">{{cite journal |author=Dickersin K ''et al.'' |title=Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards |journal=JAMA |volume=267 |pages=374–8 |year=1992 |pmid=1727960 |doi=}}</ref> and conflict of interest<ref name="pmid15916457">{{cite journal |author=Smith R |title=Medical journals are an extension of the marketing arm of pharmaceutical companies |journal=PLoS Med |volume=2  |pages=e138 |year=2005 |pmid=15916457 |doi=10.1371/journal.pmed.0020138}}</ref>. These two problems interact, as conflict of interest often leads to publication bias.<ref name="pmid12775615">{{cite journal |author=Melander H ''et al.'' |title=Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications |journal=BMJ |volume=326 |pages=1171–3 |year=2003 |pmid=12775615 |doi=10.1136/bmj.326.7400.1171}}</ref><ref name="pmid1727960">{{cite journal |author=Dickersin K ''et al.''|title=Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards |journal=JAMA |volume=267 |pages=374–8 |year=1992 |pmid=1727960 |doi=}}</ref>
|}
<!-- End of USPSTF text box -->


However an obvious important reason is that many (if not all) studies contain potential flaws in their design, and even when there are no clear methodological flaws, any outcome of a test that is evaluated by statistical test has a margin of error: this means that some positive outcomes will be "false positives".
To "'''Appraise'''" the quality of the evidence in a study is very important, as one third of the results of even the most visible medical research is eventually either attenuated or refuted.<ref name="pmid16014596"/> There are many reasons for this<ref name="pmid9546568">{{cite journal |author=Ioannidis JP ''et al.''|title=Issues in comparisons between meta-analyses and large trials |journal=JAMA |volume=279 |pages=1089–93 |year=1998 |pmid=9546568 |doi=}}</ref>; two of the most common being ''[[publication bias]]''<ref name="pmid1727960">{{cite journal |author=Dickersin K ''et al.'' |title=Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards |journal=JAMA |volume=267 |pages=374–8 |year=1992 |pmid=1727960 |doi=}}</ref> and ''[[conflict of interest]]''<ref name="pmid15916457">{{cite journal |author=Smith R |title=Medical journals are an extension of the marketing arm of pharmaceutical companies |journal=PLoS Med |volume=|pages=e138 |year=2005 |pmid=15916457 |doi=10.1371/journal.pmed.0020138}}</ref> (see article on [[Medical ethics]]). These two problems interact, as [[conflict of interest]] often leads to [[publication bias]].<ref name="pmid12775615">{{cite journal |author=Melander H ''et al.'' |title=Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications |journal=BMJ |volume=326 |pages=1171–3 |year=2003 |pmid=12775615 |doi=10.1136/bmj.326.7400.1171}}</ref><ref name="pmid1727960"/> Complicating the appraisal process further, many (if not all) studies contain  some design flaws, and even when there are no clear methodological flaws, any outcome of a test that is evaluated by ''statistical test'' has a margin of error: this means that some positive outcomes will be "false positives".
====Publication bias====
Whether a treatment or medical intervention is effective or not may be judged either on the basis of the experience of the practising physician, or on the basis of what has been published by others. The publications with greatest authority are generally those that appear in the peer-reviewed scientific journals, and particularly in those journals generally thought to have the highest standards of editorial scrutiny. However, it is no simple matter to get a study published in any peer-reviewed journal, least of all in the best journals. Accordingly, many studies go unreported. It is often thought to be particularly difficult to publish small studies, the outcome of which conflicts with the reported outcomes of larger prviously published studies, or to publish studies where the outcome is equivocal - where no clear conclusion can be drawn. In part this reflects the wish of the best journals to publish influential papers, and in part it reflects simply the fact of authors choosing not to put their energies into publishing studies that are thought to be uninteresting. Such ''publication bias'' can be difficult to recognise, but its effects generally tend to encourage publication of studies that support an already formed conclusion, while tending to discourage publication of contradictory or equivocal findings.<ref name="pmid1727960">{{cite journal |author=Dickersin K ''et al.'' |title=Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards |journal=JAMA |volume=267 |pages=374–8 |year=1992 |pmid=1727960 |doi=}}</ref><ref name="pmid12876092">{{cite journal |author=Krzyzanowska MK ''et al.''|title=Factors associated with failure to publish large randomized trials presented at an oncology meeting |journal=JAMA |volume=290 |pages=495–501 |year=2003 |pmid=12876092 |doi=10.1001/jama.290.4.495}}</ref> Publication bias may be more prevalent in industry sponsored research.<ref name="pmid12775614">{{cite journal |author=Lexchin J ''et al.''|title=Pharmaceutical industry sponsorship and research outcome and quality: systematic review |journal=BMJ |volume=326 |pages=1167–70 |year=2003 |pmid=12775614 |doi=10.1136/bmj.326.7400.1167}}</ref>


In performing a [[Meta-analysis|meta-analyses]], a file drawer<ref name="pmid11523382">{{cite journal |author=Pham B ''et al.'' |title=Is there a "best" way to detect and minimize publication bias? An empirical evaluation |journal=Evaluation & the Health Professions |volume=24 |issue=2 |pages=109–25 |year=2001 |pmid=11523382 |doi=}}</ref> or a funnel plot analysis<ref name="pmid9310563">{{cite journal |author=Egger M ''et al.'' |title=Bias in meta-analysis detected by a simple, graphical test |journal=BMJ |volume=315 |pages=629–34 |year=1997 |pmid=9310563 |doi=}}</ref><ref name="pmid16085192">{{cite journal |author=Terrin N ''et al.'' |title=In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias |journal=J Clinical Epidemiol |volume=58 |pages=894–901 |year=2005 |pmid=16085192 |doi=10.1016/j.jclinepi.2005.01.006}}</ref> may help detect underlying publication bias among the studies in the meta-analysis.
Often, only the abstract of an article will be read,<ref name="pmid11119185">{{cite journal |author=Saint S ''et al'' |title=Journal reading habits of internists |journal=J Gen Intern Med |volume=15  |pages=881–4 |year=2000 |pmid=11119185 |doi=}}</ref> but many abstracts contain errors.<ref name="pmid10188662">{{cite journal |author=Pitkin RM ''et al.''|title=Accuracy of data in abstracts of published research articles |journal=JAMA |volume=281|pages=1110–1 |year=1999 |pmid=10188662 |doi=}}</ref> These are usually errors of omission rather than contradiction, but abstracts often over-emphasise positive findings and neglect to mention limitations.  


====Conflict of interest====
When abstracts are read, readers may be biased <ref>Lord, Charles, Ross, Lee, and Lepper, Mark (1979). '[http://www.psych.umn.edu/courses/spring07/borgidae/psy5202/readings/lord,%20ross%20&%20lepper%20(1979).pdf Biased Assimilation and Attitude Polarization: The Effects of Prior Theories on Subsequently Considered Evidence]',Journal of Personality and Social Psychology, 37 (11): 2098-2109. </ref> and make illogical conclusions<ref name="pmid3701813">{{cite journal |author=Bergman DA, Pantell RH |title=The impact of reading a clinical study on treatment decisions of physicians and residents |journal=J Med Educ |volume=61 |issue=5 |pages=380–6 |year=1986 |month=May |pmid=3701813 |doi= |url= |issn=}}</ref>.
In any publication, there is always some issue with regard to conflict of interest. All the work by scientists is funded by groups such as charities, public bodies or private industry. Accordingly there could be pressure to overstate any outcomes or bias a trial to favor a particular outcome. Unfortunately, the presence of authors with a conflict of interest is not reliably indicated in journal articles.<ref name="pmid11405896">{{cite journal |author=Papanikolaou GN ''et al.''|title=Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions |journal=BMC medical research methodology |volume=1  |pages=3 |year=2001 |pmid=11405896 |doi=}}</ref> Worse it has been reported that some published articles use 'ghost writers'.<ref name="pmid16230729">{{cite journal |author=Laine C, Mulrow CD |title=Exorcising ghosts and unwelcome guests |journal=Ann Intern. Med |volume=143  |pages=611–2 |year=2005 |pmid=16230729 |doi=|url=http://www.annals.org/cgi/content/full/143/8/611}}</ref> Ghost writers may have a conflict of interest but this is not apparent since they are not credited as an author in the byline. Finally, academic scientists gain their professional reputations by publishing in quality journals and purely factual summaries do not necessarily impress journal editors any more than they inspire casual readers.  


In the design of [[randomized controlled trial]]s, industry-sponsored studies may be more likely to select an inappropriate comparator group that would favor finding benefit in the experimental group. This may manifest itself by comparing the effectiveness of a new drug with the effectiveness of an established older treatment rather than choosing a competitors current treatment for comparison.<ref name="pmid12775614">{{cite journal |author=Lexchin J ''et al.'' |title=Pharmaceutical industry sponsorship and research outcome and quality: systematic review |journal=BMJ |volume=326 |pages=1167–70 |year=2003 |pmid=12775614 |doi=10.1136/bmj.326.7400.1167}}</ref> When reporting data from randomized controlled trials, industry-sponsored studies may be more likely to omit [[intention-to-treat]] analyses.<ref name="pmid12775615">{{cite journal |author=Melander H ''et al.'' |title=Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications |journal=BMJ |volume=326 |pages=1171–3 |year=2003 |pmid=12775615 |doi=10.1136/bmj.326.7400.1171}}</ref> Regarding the conclusions reached in randomized controlled trials,  industry sponsored studies may be more likely to conclude that drugs are safe, even when they have increased adverse effects.<ref name="pmid17954797">{{cite journal |author=Nieto A ''et al.'' |title=Adverse effects of inhaled corticosteroids in funded and nonfunded studies |journal=Arch Intern Med |volume=167 |pages=2047–53 |year=2007 |pmid=17954797 |doi=10.1001/archinte.167.19.2047}}</ref> Alternatively, the usefulness of drugs may be overstated, although, this is contentious since one study did not find evidence of overstatement.<ref name="pmid10535436">{{cite journal |author=Friedberg M ''et al.'' |title=Evaluation of conflict of interest in economic analyses of new drugs used in oncology |journal=JAMA |volume=282 |pages=1453–7 |year=1999 |pmid=10535436 |doi=}}</ref> in contrast, a later study found that industry sponsored studies are more likely to recommend the experimental drug as treatment of choice even after adjusting for the treatment effect.<ref name="pmid12928469">{{cite journal |author=Als-Nielsen B ''et al.''|title=Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? |journal=JAMA |volume=290 |pages=921–8 |year=2003 |pmid=12928469 |doi=10.1001/jama.290.7.921}}</ref>
The initial steps in reading an article are determining what the article's conclusion and whether its conclusion, if valid, is important.<ref name="pmid7471000">{{cite journal| author=| title=How to read clinical journals: I. why to read them and how to start reading them critically. | journal=Can Med Assoc J | year= 1981 | volume= 124 | issue= 5 | pages= 555-8 | pmid=7471000 | doi= | pmc=PMC1705173 | url= }} </ref>


Obviously a pharmaceutical company wants to report that its drug is better than a competitor's drug, or better than no treatment, however, due to the threat of litigation, it is not in their interests to suppress or minimise evidence of harm. For the scientists who are conducting the trials, however, the perspective might different: if it becomes clear that a drug is useless or harmful, then the company will cease to work on the drug and a scientists livelyhood could be threatened. Consequently, the responsibility for the integrity of the design and analysis of studies lies squarely with the authors. If the scientists involved in any trial are lacking in competence or integrity, then this will prejudice the value of a trial both for the public and indeed for their industrial sponsors.
Overall risk in the population in a study can be assessed by examining outcome rr prevalence rates in the control groups.<ref name="pmid16613605">{{cite journal| author=Hayward RA, Kent DM, Vijan S, Hofer TP| title=Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. | journal=BMC Med Res Methodol | year= 2006 | volume= 6 | issue=  | pages= 18 | pmid=16613605 | doi=10.1186/1471-2288-6-18 | pmc=PMC1523355 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16613605  }} </ref>


====Statistical analysis====
Automated text mining can help assess the quality of an article.<ref name="pmid21707873">{{cite journal| author=Lin JW, Chang CH, Lin MW, Ebell MH, Chiang JH| title=Automating the process of critical appraisal and assessing the strength of evidence with information extraction technology. | journal=J Eval Clin Pract | year= 2011 | volume=  | issue= | pages= | pmid=21707873 | doi=10.1111/j.1365-2753.2011.01712.x | pmc= | url= }} </ref>
Statistical analysis of the outcomes of a clinical trial is a complex and highly technical process. These often require the involvement of a professional medical statistician whose advice is needed in the design of the trial as well as in the analysis of its outcome. Flaws in the design of a trial can lead subsequently to weaknesses in statistical analysis. Ideally, a trial protocol should be carefully designed with statistical issues in mind, and with the hypothesis under test clearly formulated, and the agreed protocol should then be strictly adhered to. Often however problems arise during the test; for example, there may be unanticipated outcomes of the trial, or problems in patient recruitment or in compliance with the test protocol, and these problems can weaken the power and authority of the trial. Common problems include small sample sizes in some of the groups<ref name="pmid17975858">{{cite journal |author=Glasziou P, Doll H |title=Was the study big enough? Two "café" rules (Editorial) |journal=ACP J Club |volume=147 |pages=A08 |year=2007 |pmid=17975858 |doi=}}</ref>, problems of "multiple comparisons" when several different outcomes are being assessed, and biasing of study populations by selection criteria.


The outcome of a trial or study is often summarised by calculation of a "P-value" that expresses the likelihood that an observed difference (between treatment groups reflects a true difference in treatment effectiveness; the P value is a statistical calculation of the chance that the observed apparent difference reflects the chance outcome of random sampling. Some have argued that focussing on P values neglects other important sources of knowledge and information that should properly be used to assess the likely efficacy of a treatment <ref name="pmid10383371">{{cite journal |author=Goodman SN |title=Toward evidence-based medical statistics. 1: The P value fallacy |journal=Ann Intern Med |volume=130 |pages=995–1004 |year=1999 |pmid=10383371 |doi=|url=http://www.annals.org/cgi/content/full/130/12/995}}</ref> In particular, some argue that the P-value should be interpreted in light of how plausible is the hypothesis based on the totality of prior research and physiologic knowledge.<ref name="pmid3573245">{{cite journal |author=Browner WS, Newman TB |title=Are all significant P values created equal? The analogy between diagnostic tests and clinical research |journal=JAMA |volume=257  |pages=2459–63 |year=1987 |pmid=3573245 |doi=}}</ref><ref name="pmid10383371"/><ref name="pmid10383350">{{cite journal |author=Goodman SN |title=Toward evidence-based medical statistics. 2: The Bayes factor |journal=Ann Intern Med |volume=130 |pages=1005–13 |year=1999 |pmid=10383350 |doi=|url=http://www.annals.org/cgi/content/full/130/12/1005}}</ref>
"Levels of evidence" are used for describing the strength of a research study.<ref name="pmid115569">{{cite journal| author=| title=The periodic health examination. Canadian Task Force on the Periodic Health Examination. | journal=Can Med Assoc J | year= 1979 | volume= 121 | issue= 9 | pages= 1193-254 | pmid=115569
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=115569 | pmc=PMC1704686 }}</ref><ref name="titleLevels of Evidence">{{cite web |url=http://www.eboncall.org/content/levels.html |title=Levels of Evidence |accessdate=2007-12-31 |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> The [http://www.equator-network.org/ Equator network] is a collection of standards to improve the reporting of health research. An example is the [http://www.consort-statement.org/ Consort statement] for the reporting of randomized controlled trials.
 
Guides exist for assessing a body of literature; these are discussed below, [[Evidence-based medicine#Assessing a body of research evidence|Assessing a body of research evidence]].
 
;Common threats to validity
'''Publication bias''' <br/>
[[Publication bias]] is "the influence of study results on the chances of publication [in [[academic journal]]s] and the tendency of investigators, reviewers, and editors to submit or accept manuscripts for publication based on the direction or strength of the study findings. Publication bias has an impact on the interpretation of clinical trials and meta-analyses. Bias can be minimized by insistence by editors on high-quality research, thorough literature reviews, acknowledgment of conflicts of interest, modification of peer review practices, etc."<ref name="title">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2007/MB_cgi?term=publication+bias |title=Publication bias |accessdate=2007-12-17 |author=National Library of Medicine |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref>
 
'''Conflict of interest'''<br/>
{{main|Conflict of interest}}
The presence of a conflict of interest has many effects in medical publishing.
 
'''Statistical analysis'''<br/>
Common problems include small sample sizes in subgroup analyses<ref name="pmid17975858">{{cite journal |author=Glasziou P, Doll H |title=Was the study big enough? Two "café" rules (Editorial) |journal=ACP J Club |volume=147  |pages=A08 |year=2007 |pmid=17975858 |doi=}}</ref>, problems of "multiple comparisons" when several outcomes are being assessed, and biasing of study populations by selection criteria.
 
Problems may arise from interim analyses of [[randomized controlled trial]]s which may lead to exaggerated estimations of treatment effects.<ref name="pmid16264162">{{cite journal |author=Montori VM ''et al'' |title=Randomized trials stopped early for benefit: a systematic review |journal=JAMA |volume=294  |pages=2203–9 |year=2005 |month=November |pmid=16264162 |doi=10.1001/jama.294.17.2203 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=16264162 |issn=}}</ref><ref>Trotta, F ''et al.'' (2008) Stopping a trial early in oncology: for patients or for industry? Ann Oncol mdn042. http://dx.doi.org/10.1093/annonc/mdn042</ref> <ref name="pmid15014189">{{cite journal |author=Slutsky AS, Lavery JV |title=Data Safety and Monitoring Boards |journal=N Engl J Med |volume=350 |pages=1143–7 |year=2004 |pmid=15014189 |doi=10.1056/NEJMsb033476 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15014189&promo=ONFLNS19 |issn=}}</ref>
 
Statistical significance:<br/>
The [[statistical significance]] of the outcome of a study is often summarized by a "P-value" that expresses the likelihood that an observed difference between treatment groups reflects a true difference in treatment effect; the P value is a calculation of the chance that the observed difference reflects the chance outcome of random sampling. Some have argued that focusing on P values neglects other important sources of knowledge and information that should be used to assess the likely efficacy of a treatment <ref name="pmid10383371">{{cite journal |author=Goodman SN |title=Toward evidence-based medical statistics. 1: The P value fallacy |journal=Ann Intern Med |volume=130 |pages=995–1004 |year=1999 |pmid=10383371 |doi=|url=http://www.annals.org/cgi/content/full/130/12/995}}</ref> In particular, some argue that the P-value should be interpreted in light of how plausible is the hypothesis based on the totality of prior research and physiologic knowledge.<ref name="pmid3573245">{{cite journal |author=Browner WS, Newman TB |title=Are all significant P values created equal? The analogy between diagnostic tests and clinical research |journal=JAMA |volume=257  |pages=2459–63 |year=1987 |pmid=3573245 |doi=}}</ref><ref name="pmid10383371"/><ref name="pmid10383350">{{cite journal |author=Goodman SN |title=Toward evidence-based medical statistics. 2: The Bayes factor |journal=Ann Intern Med |volume=130 |pages=1005–13 |year=1999 |pmid=10383350 |doi=|url=http://www.annals.org/cgi/content/full/130/12/1005}}</ref> Bayesian inference formalizes this approach to [[statistical significance]].


===Application===
===Application===
It is important to "'''apply'''" the best practices found to the correct situation. One of the common problems in applying evidence are difficulties with numeracy. Both patients and healthcare professionals have difficulties with health numeracy and probabilistic reasoning.<ref name="pmid17712082">{{cite journal |author=Ancker JS, Kaufman D |title=Rethinking Health Numeracy: A Multidisciplinary Literature Review |journal= |volume=  |pages= |year=2007 |pmid=17712082 |doi=10.1197/jamia.M2464}}</ref> A second problem is to recognise the patient population that will benefit from the new practices. Extrapolating study results to the wrong patient populations (over-generalization)<ref name="pmid11147985">{{cite journal |author=Gross CP ''et al.'' |title=Relation between prepublication release of clinical trial results and the practice of carotid endarterectomy |journal=JAMA |volume=284 |pages=2886–93 |year=2000 |pmid=11147985 |doi= |issn=}}</ref><ref name="pmid15295047">{{cite journal |author=Juurlink DN ''et al.'' |title=Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study |journal=N Engl J Med |volume=351  |pages=543–51 |year=2004 |pmid=15295047 |doi=10.1056/NEJMoa040135 |issn=}}</ref><ref name="pmid17488964">{{cite journal |author=Beohar N ''et al.'' |title=Outcomes and complications associated with off-label and untested use of drug-eluting stents |journal=JAMA |volume=297|pages=1992–2000 |year=2007 |pmid=17488964 |doi=10.1001/jama.297.18.1992 |issn=}}</ref> and not applying study results to the correct population (under-utilization)<ref name="pmid8990335">{{cite journal |author=Soumerai SB ''et al.'' |title=Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction |journal=JAMA |volume=277 |pages=115–21 |year=1997 |pmid=8990335 |doi=}}</ref><ref name="pmid11228280">{{cite journal |author=Hemingway H ''et al.'' |title=Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization |journal=N Engl J Med |volume=344 |pages=645–54 |year=2001 |pmid=11228280 |doi=}}</ref> can both increase adverse outcomes.
It is important to "'''apply'''" the best practices found to the correct situation. One common problem in applying evidence is that both patients and healthcare professionals often have difficulties with [[quantitative literacy|health numeracy]] and probabilistic reasoning.<ref name="pmid17712082">{{cite journal |author=Ancker JS, Kaufman D |title=Rethinking health numeracy: a multidisciplinary literature review |journal= |volume=  |pages= |year=2007 |pmid=17712082 |doi=10.1197/jamia.M2464}}</ref> Another problem is successful clinical reasoning at the bedside.<ref name="pmid3736379">{{cite journal |author=Dubeau CE ''et al.''|title=Premature conclusions in the diagnosis of iron-deficiency anemia: cause and effect |journal=Med Decis Making |volume=6  |pages=169–73 |year=1986 |pmid=3736379 |doi=}}</ref> Successful reasoning is associated with the use of pattern matching <ref name="pmid12895249">{{cite journal |author=Coderre S ''et al.'' |title=Diagnostic reasoning strategies and diagnostic success |journal=Med Educ |volume=37  |pages=695–703 |year=2003 |pmid=12895249 |doi=}}</ref><ref name="pmid7070446">{{cite journal |author=Eddy DM, Clanton CH |title=The art of diagnosis: solving the clinicopathological exercise |journal=N Engl J Med |volume=306  |pages=1263–8 |year=1982 |pmid=7070446 |doi=}}</ref> and recognizing clinical findings that are "pivot" or specific to certain diseases<ref name="pmid7070446"/>. A third problem is to identify exactly which patients will benefit from the new practices. Extrapolating study results to the wrong patient populations (over-generalization)<ref name="pmid11147985">{{cite journal |author=Gross CP ''et al.'' |title=Relation between prepublication release of clinical trial results and the practice of carotid endarterectomy |journal=JAMA |volume=284 |pages=2886–93 |year=2000 |pmid=11147985 |doi= |issn=}}</ref><ref name="pmid15295047">{{cite journal |author=Juurlink DN ''et al.'' |title=Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study |journal=N Engl J Med |volume=351  |pages=543–51 |year=2004 |pmid=15295047 |doi=10.1056/NEJMoa040135 |issn=}}</ref><ref name="pmid17488964">{{cite journal |author=Beohar N ''et al.'' |title=Outcomes and complications associated with off-label and untested use of drug-eluting stents |journal=JAMA |volume=297|pages=1992–2000 |year=2007 |pmid=17488964 |doi=10.1001/jama.297.18.1992 |issn=}}</ref> and not applying study results to the correct population (under-utilization)<ref name="pmid8990335">{{cite journal |author=Soumerai SB ''et al.'' |title=Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction |journal=JAMA |volume=277 |pages=115–21 |year=1997 |pmid=8990335 |doi=}}</ref><ref name="pmid11228280">{{cite journal |author=Hemingway H ''et al.'' |title=Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization |journal=N Engl J Med |volume=344 |pages=645–54 |year=2001 |pmid=11228280 |doi=}}</ref> can both increase adverse outcomes.


The problem in over-generalization of study results may be more common among specialist physicians.<ref name="pmid11422641">{{cite journal |author=Turner BJ, Laine C |title=Differences between generalists and specialists: knowledge, realism, or primum non nocere? |journal=J Gen Intern Med |volume=16  |pages=422-4 |year=2001 |pmid=11422641 |doi=10.1046/j.1525-1497.2001.016006422.x}} [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=wikipedia&pubmedid=11422641 PubMed Central]</ref> Two studies found specialists were more likely to adopt [[cyclooxygenase 2 inhibitors|cyclooxygenase 2 inhibitor]] drugs before the drug [[rofecoxib]] was withdrawn by its manufacturers after it emerged that its use had unanticipated adverse effects <ref name="pmid15755796">{{cite journal |author=Rawson N ''et al.'' |title=Factors associated with celecoxib and rofecoxib utilization |journal=Ann Pharmacother |volume=39 |pages=597-602 |year=2005 |pmid=15755796}}</ref><ref name="pmid16808768">{{cite journal |author=De Smet BD ''et al.'' |title=Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited |journal=J Gen Intern Med |volume=21 |pages=694-7 |year=2006 |pmid=16808768 |doi=10.1111/j.1525-1497.2006.00463.x}}</ref>. One of the studies went on to state:
The problem of over-generalizating study results may be more common among specialist physicians.<ref name="pmid11422641">{{cite journal |author=Turner BJ, Laine C |title=Differences between generalists and specialists: knowledge, realism, or primum non nocere? |journal=J Gen Intern Med |volume=16  |pages=422-4 |year=2001 |pmid=11422641 |doi=10.1046/j.1525-1497.2001.016006422.x}} [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=wikipedia&pubmedid=11422641 PubMed Central]</ref> Two studies found specialists were more likely to adopt [[cyclooxygenase 2 inhibitors|cyclooxygenase 2 inhibitor]] drugs before the drug [[rofecoxib]] was withdrawn by its manufacturers because of its unanticipated adverse effects <ref name="pmid15755796">{{cite journal |author=Rawson N ''et al.'' |title=Factors associated with celecoxib and rofecoxib utilization |journal=Ann Pharmacother |volume=39 |pages=597-602 |year=2005 |pmid=15755796}}</ref><ref name="pmid16808768">{{cite journal |author=De Smet BD ''et al.'' |title=Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited |journal=J Gen Intern Med |volume=21 |pages=694-7 |year=2006 |pmid=16808768 |doi=10.1111/j.1525-1497.2006.00463.x}}</ref>. One of the studies went on to state:
::"''using COX-2s as a model for physician adoption of new therapeutic agents, specialists were more likely to use these new medications for patients likely to benefit but were also significantly more likely to use them for patients without a clear indication''".<ref name="pmid16808768"/>  
::"''using COX-2s as a model for physician adoption of new therapeutic agents, specialists were more likely to use these new medications for patients likely to benefit but were also significantly more likely to use them for patients without a clear indication''".<ref name="pmid16808768"/>  
Similarly, orthopedists may provide more intensive care for back pain, but without benefit from the increased care.<ref name="pmid7666878">{{cite journal | author = Carey T ''et al.''| title = The outcomes and costs of care for acute low back pain among patients seen by primary care practitioners, chiropractors, and orthopedic surgeons. The North Carolina Back Pain Project | journal = N Engl J Med | volume = 333 |pages = 913-7 | year = 1995 | id = PMID 7666878}}</ref>   
Similarly, orthopedists provide more expensive care for back pain, but without measurably increased benefit compared to other types of practitioners.<ref name="pmid7666878">{{cite journal | author = Carey T ''et al.''| title = The outcomes and costs of care for acute low back pain among patients seen by primary care practitioners, chiropractors, and orthopedic surgeons. The North Carolina Back Pain Project | journal = N Engl J Med | volume = 333 |pages = 913-7 | year = 1995 | id = PMID 7666878}}</ref>  Some of the reason that subspecialists may be more likely to adopt inadequately studied innovations is that they read from a spectrum of [[academic journal|journals]] that have less consistent quality.<ref name="pmid17641754">{{cite journal |author=McKibbon KA ''et al.'' |title=Which journals do primary care physicians and specialists access from an online service? |journal= JMLA |volume=95 |pages=246-54 |year=2007 |pmid=17641754 |doi=10.3163/1536-5050.95.3.246}}</ref> Articles from specialty [[academic journal|journals]] have been noted to persist in supporting claims in the medical literature that have been refuted.<ref name=pmidpending_Tatsioni">Tatsioni A, Bonitsis NG, Ioannidis JPA (2007) Persistence of contradicted claims in the literature. ''JAMA'' [http://jama.ama-assn.org/cgi/content/abstract/298/21/2517 298]</ref>


The problem of under-utilizing study results may be more common when physicians are practicing outside of their expertise. For example, specialist physicians are less likely to under-utilize specialty care<ref name="pmid11422631">{{cite journal | author = Majumdar S ''et al.'' | title = Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction | journal = J Gen Intern Med | volume = 16 |  pages = 351-9 | year = 2001 | id = PMID 11422631}}</ref><ref name="pmid8759658">{{cite journal | author = Fendrick A, Hirth R, Chernew M | title = Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease | journal = Am J Gastroenterol | volume = 91 | pages = 1544-8 | year = 1996 | id = PMID 8759658}}</ref>, while primary care physicians are less likely to under-utilize  preventive care<ref name="pmid1983933">{{cite journal | author = Lewis C ''et al.'' | title = The counseling practices of internists | journal = Ann Intern Med | volume = 114 | pages = 54-8 | year = 1991 | id = PMID 1983933}}</ref><ref name="pmid1599724">{{cite journal | author = Turner B ''et al.'' | title = Breast cancer screening: effect of physician specialty, practice setting, year of medical school graduation, and sex | journal = Am J Prev Med | volume = 8 |  pages = 78-85 | year = | id = PMID 1599724}}</ref>.
The problem of under-utilizing study results may be more common when physicians are practising outside their expertise. For example, specialist physicians are less likely to under-utilize specialty care<ref name="pmid11422631">{{cite journal | author = Majumdar S ''et al.'' | title = Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction | journal = J Gen Intern Med | volume = 16 |  pages = 351-9 | year = 2001 | id = PMID 11422631}}</ref><ref name="pmid8759658">{{cite journal | author = Fendrick A ''et al.'' | title = Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease | journal = Am J Gastroenterol | volume = 91 | pages = 1544-8 | year = 1996 | id = PMID 8759658}}</ref>, while primary care physicians are less likely to under-utilize  preventive care<ref name="pmid1983933">{{cite journal | author = Lewis C ''et al.'' | title = The counseling practices of internists | journal = Ann Intern Med | volume = 114 | pages = 54-8 | year = 1991 | id = PMID 1983933}}</ref><ref name="pmid1599724">{{cite journal | author = Turner B ''et al.'' | title = Breast cancer screening: effect of physician specialty, practice setting, year of medical school graduation, and sex | journal = Am J Prev Med | volume = 8 |  pages = 78-85 | year = | id = PMID 1599724}}</ref>.


==Metrics used in evidence-based medicine==
==Metrics used in EBM==
===Diagnosis===
:'''Diagnosis'''
* Sensitivity and specificity
*   [[Sensitivity and specificity]]
* Likelihood ratios ([[Odds ratio]]s)
*   [[Likelihood ratio]]s


===Interventions===
:'''Causation'''
====Relative measures====
::''Relative measures''
* Relative risk ratio
*   [[Odds ratio]]
* Relative risk reduction
Relative risk ratio
*   [[Relative risk reduction]]


====Absolute measures====
::''Absolute measures''
* Absolute risk reduction
*   [[Absolute risk reduction]]
* Number needed to treat
*   [[Number needed to treat]] (NNT)<ref name="pmid3374545">{{cite journal |author=Laupacis A ''et al.'' |title=An assessment of clinically useful measures of the consequences of treatment |journal=N Engl J Med |volume=318 |pages=1728–33 |year=1988 |pmid=3374545 |doi=}}</ref>
* Number needed to screen
*   [[Number needed to screen]]<ref name="pmid9685274">{{cite journal |author=Rembold CM |title=Number needed to screen: development of a statistic for disease screening |journal=BMJ |volume=317 |pages=307–12 |year=1998 |pmid=9685274 |doi= |issn=|url=http://www.bmj.com/cgi/content/full/317/7154/307}}</ref>
* Number needed to harm
*   [[Number needed to harm]]


===Health policy===
:'''Health policy''' {{main|Cost-benefit analysis}}
* Cost per year of life saved<ref name="pmid7604170">{{cite journal |author=Tengs TO ''et al'' |title=Five-hundred life-saving interventions and their cost-effectiveness |journal=Risk Anal |volume=15 |pages=369–90 |year=1995 |pmid=7604170 |doi=}}</ref>
*   Cost per year of life saved<ref name="pmid7604170">{{cite journal |author=Tengs TO ''et al'' |title=Five-hundred life-saving interventions and their cost-effectiveness |journal=Risk Anal |volume=15 |pages=369–90 |year=1995 |pmid=7604170 |doi=}}</ref>
* Years (or months or days) of life saved. "A gain in life expectancy of a month from a preventive intervention  targeted at populations at average risk and a gain of a year  from a preventive intervention targeted at populations at elevated risk can both be considered large."<ref name="pmid9691106">{{cite journal |author=Wright JC, Weinstein MC |title=Gains in life expectancy from medical interventions--standardizing data on outcomes |journal=N Engl J Med |volume=339 |pages=380–6 |year=1998 |pmid=9691106 |doi=}}</ref>
*   Cost of Preventing an Event (COPE)<ref name="pmid18170986">{{cite journal |author=Maharaj R |title=Adding cost to NNT: the COPE statistic |journal=ACP J. Club |volume=148 |pages=A8 |year=2008 |pmid=18170986 |doi= |issn=|url=http://www.acpjc.org/Content/148/1/issue/ACPJC-2008-148-1-A08.htm}}</ref>. For example, to prevent a major vascular event n a high-risk adult , the [[number needed to treat]] is 19, the number of years of treatment are 5, and the daily cost of the generic drug is 68 cents. The COPE is 19 * 5 * ( 365 * .68) which equals $23,579 in the United States.
Years (or months or days) of life saved. "A gain in life expectancy of a month from a preventive intervention  targeted at populations at average risk and a gain of a year  from a preventive intervention targeted at populations at elevated risk can both be considered large."<ref name="pmid9691106">{{cite journal |author=Wright JC, Weinstein MC |title=Gains in life expectancy from medical interventions--standardizing data on outcomes |journal=N Engl J Med |volume=339 |pages=380–6 |year=1998 |pmid=9691106 |doi=}}</ref>


==Experimental trials: producing the evidence==
==Original research studies: levels of evidence==
{{main|Randomized controlled trial}}
'Levels of evidence' were first proposed in 1979 bye the Canadian Task Force on the Periodic Health Examination<ref name="pmid115569"/> then modified by the American College of Chest Physicians<ref name="pmid2914516">{{cite journal| author=Sackett DL| title=Rules of evidence and clinical recommendations on the use of antithrombotic agents. | journal=Chest | year= 1989 | volume= 95 | issue= 2 Suppl | pages= 2S-4S | pmid=2914516
{|align="right" cellpadding="10" style="background-color:#FFFFCC; width:50%; border: 1px solid #aaa; margin:20px; font-size: 92%;"
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=2914516 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref><ref name="pmid3943408">{{cite journal |author=Sackett DL |title=Rules of evidence and clinical recommendations on the use of antithrombotic agents |journal=Chest |volume=89  |pages=2S–3S |year=1986 |pmid=3943408 |doi=}}</ref> to create a framework for judging the strength of research. An example of levels of evidence is, based on prior work<ref name="titleLevels of Evidence">{{cite web |url=http://www.eboncall.org/content/levels.html |title=Levels of Evidence |accessdate=2007-12-31 |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref>:
|
* Level 1 - [[Randomized controlled trial]]s
''In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic measure, if in his or her judgement it offers hope of saving life, re-establishing health or alleviating suffering.  
* Level 2 - [[Cohort study|Cohort studies]]
* Level 3 - [[Case control study|Case control studies]]
* Level 4 - [[Case series]] and [[case report]]s. The important role of case reports have been described.<ref name="pmid18350575">{{cite journal |author=Sethi NK, Sethi PK |title=Evidence-based medicine vs medicine-based evidence |journal=Ann. Neurol. |volume= |issue= |pages= |year=2008 |pmid=18350575 |doi=10.1002/ana.21354 |url=http://dx.doi.org/10.1002/ana.21354}}</ref>


''The potential benefits, hazards and discomfort of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods.  
These levels of evidence have been criticized as only representing one of two views of medical science.<ref>{{Cite journal | doi =  10.1371/journal.pmed.0050067 | volume = 5 | issue = 3 | pages = e67 EP - | last = Vandenbroucke | first = JP | title = Observational research, randomised trials, and two views of medical science | journal = PLoS Medicine | accessdate = 2008-03-11 | date = 2008-03-01 | url = http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050067 }}</ref> Vandenbroucke proposes that the two views of medical research are:
# Evaluation of interventions. In this view, the [[randomized controlled trial]] is most important.
# Discovery and explanation. In this view, the [[randomized controlled trial]] is not supreme and observational studies, subgroup analyses, and secondary analyses are important.


''In any medical study, every patient- including those of a control group, if any- should be assured of the best proven diagnostic and therapeutic method.  
In practice, [[randomized controlled trial]]s are available to support only 21%<ref name="pmid9701101">{{cite journal |author=Michaud G ''et al.'' |title=Are therapeutic decisions supported by evidence from health care research? |journal=Arch Intern Med |volume=158 |pages=1665–8 |year=1998 |pmid=9701101 |doi=}}</ref> to 53%<ref name="pmid7623571">{{cite journal |author=Ellis J ''et al.''|title=Inpatient general medicine is evidence based. A-Team, Nuffield Department of Clinical Medicine |journal=Lancet |volume=346  |pages=407–10 |year=1995 |pmid=7623571 |doi=}}</ref> of principal therapeutic decisions.<ref>{{cite web |url=http://www.shef.ac.uk/scharr/ir/percent.html |title=Percentage of practice that is evidence based? |accessdate=2007-11-15 |author=Booth A |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> Due to this, evidence-based medicine has evolved to accept lesser levels of evidence when randomized controlled trials are not available.<ref name="pmid17213159">{{cite journal |author=Haynes RB |title=Of studies, syntheses, synopses, summaries, and systems: the "5S" evolution of information services for evidence-based healthcare decisions |journal=Evidence-based Medicine |volume=11 |pages=162–4 |year=2006 |pmid=17213159 |doi=10.1136/ebm.11.6.162-a}}</ref>


''The refusal of the patient to participate in a study must never interfere with the physician-patient relationship.  
The [http://www.gradeworkinggroup.org/ Grade Working Group] recognizes that assessing medical evidence involves attention to other dimensions than study design, and expanded upon the levels of evidence in 2004.<ref name="pmid15205295">{{cite journal |author=Atkins D ''et al'' |title=Grading quality of evidence and strength of recommendations |journal=BMJ |volume=328  |pages=1490 |year=2004 |pmid=15205295 |doi=10.1136/bmj.328.7454.1490 |url=http://bmj.com/cgi/pmidlookup?view=long&pmid=15205295}}</ref><ref name="pmid16388549">{{cite journal |author=Guyatt G, ''et al.'' |title=An emerging consensus on grading recommendations? |journal=ACP J Club |volume=144 |pages=A8–9 |year=2006 |pmid=16388549 |doi= |url=http://www.acpjc.org/Content/144/1/Issue/ACPJC-2006-144-1-A08.htm}}</ref> These dimensions include: study design; study quality; consistency of study results; and directness (e.g. how close does the research study mirror clinical practice)


''If the physician considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee.  
==Summarizing the evidence==
===Assessing a body of research evidence===
Several systems have been proposed to assess whether a body of research evidence establishes causality.


''The physician can combine medical research with professional care, the objective being the acquisition of new medical knowledge,only to the extent that medical research is justified by its potential diagnostic or therapeutic value for the patient.  
{|align="right" cellpadding="10" style="background-color:#FFFFCC; width:50%; border: 1px solid #aaa; margin:20px; font-size: 92%;"
|'''Koch's postulates'''<ref name="pmid15372724">{{cite journal| author=Hopayian K| title=Why medicine still needs a scientific foundation: restating the hypotheticodeductive model - part two. | journal=Br J Gen Pract | year= 2004 | volume= 54 | issue= 502 | pages= 402-3; discussion 404-5 | pmid=15372724
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15372724 | pmc=PMC1266186 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
* "The bacterium must be present in every case of the disease."
* "The bacterium must be isolated from the diseased host and grown in pure culture."
* "The specific disease must be reproduced when a pure culture of the bacterium is inoculated into a healthy susceptible host."
* "The bacterium must be recoverable from the experimentally infected host."
|}
In the 1880's Koch proposed postulates ([[Koch's Postulates]]) that suggest association.<ref name="pmid16339091">{{cite journal |author=Kaufmann SH |title=Robert Koch, the Nobel Prize, and the ongoing threat of tuberculosis |journal=N. Engl. J. Med. |volume=353 |issue=23 |pages=2423–6 |year=2005 |month=December |pmid=16339091 |doi=10.1056/NEJMp058131 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=16339091&promo=ONFLNS19 |issn=}}</ref> However, even though the postulates focus on establishing casuality among infections diseases, examples have emerged that violate his postulates.<ref name="pmid15372724">{{cite journal| author=Hopayian K| title=Why medicine still needs a scientific foundation: restating the hypotheticodeductive model - part two. | journal=Br J Gen Pract | year= 2004 | volume= 54 | issue= 502 | pages= 402-3; discussion 404-5 | pmid=15372724
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15372724 | pmc=PMC1266186 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


From '''The Declaration of Helsinki''' <ref>World Medical Organization. (1996) [http://www.cirp.org/library/ethics/helsinki/ Declaration of Helsinki]. ''British Medical Journal'' '''313''':1448-1449. hosted at cirp.org</ref>
{|align="right" cellpadding="10" style="background-color:#FFFFCC; width:50%; border: 1px solid #aaa; margin:20px; font-size: 92%;"
|'''Bradford Hill criteria'''<ref name="pmid14283879">{{cite journal |author=Hill AB |title=The Environment And Disease: Association Or Causation? |journal=Proc. R. Soc. Med. |volume=58 |pages=295–300 |year=1965 |month=May |pmid=14283879 |pmc=1898525 |doi= |url= |issn=}}</ref>
* Strength or magnitude of association?
* Consistency of association across studies?
* Specificity of association?
* Temporality of association?
* Plausibility based on biological knowledge?
* Biological gradient: or dose-response relationship?
* Coherence? Does the proposed association explain other observations?
* Experimental evidence?
* Analogy?
|}
|}


"A clinical trial is defined as a prospective scientific experiment that involves human subjects in whom treatment is initiated for the evaluation of a therapeutic intervention. In a randomized controlled clinical trial, each patient is assigned to receive a specific treatment intervention by a chance mechanism."<ref name="pmid17339574">{{cite journal |author=Stanley K |title=Design of randomized controlled trials |journal=Circulation |volume=115 |issue=9 |pages=1164–9 |year=2007 |pmid=17339574 |doi=10.1161/CIRCULATIONAHA.105.594945}}</ref> The theory behind these trials is that the value of a treatment will be shown in an objective way, and, though usually unstated, there is an assumption that the results of the trial will be applicable to the care of patients who have the condition that was treated.
The [[Bradford Hill]] criteria were proposed in 1965 in response to studies of the association between [[tobacco]] and [[lung cancer]]:<ref name="pmid14283879">{{cite journal |author=Hill AB |title=The Environment And Disease: Association Or Causation? |journal=Proc. R. Soc. Med. |volume=58 |pages=295–300 |year=1965 |month=May |pmid=14283879 |pmc=1898525 |doi= |url= |issn=}}</ref>


The best evidence is thought to come from large multicentre clinical trials that are randomised and placebo-controlled, and which are conducted double-blind according to a predetermined schedule that is strictly adhered to. Trials should be large, so that serious adverse events might be detected even when they occur rarely. Multi-centre trials minimise problems that can arise when a single geographical locus has a population that is not fully representative of the global population, and they can minimise the effect of geographical variations in environment and health care delivery. Randomisation (if the study population is large enough) should mean that the study groups are unbiased. A double-blind trial is one in which neither the patient nor the deliverer of the treatment is aware of the nature of the treatment offered to any particular individual, and this avoids bias caused by the expectations of either the doctor or the patient. Placebo controls are important, because the [[placebo effect]] can often be very strong.
More explicit methods have been proposed by groups such as the [[U.S. Preventive Services Task Force]] (USPSTF) (see yellow text box above), the American College of Chest Physicians<ref name="pmid2914516"/><ref name="pmid3943408"/> and the Grade Working Group<ref name="titleGRADE working group">{{cite web |url=http://www.gradeworkinggroup.org/ |title=GRADE working group |accessdate=2007-11-23 |format= |work=}}</ref> The Grade Working Group combines the quality of research studies with their clinical relevance.<ref name="pmid15205295"/> For example, this allows comparing a randomized control trial in a population that is not exactly like the population of interest versus a cohort study that is from a relevant population. The concept that there are multiple dimensions in assessing evidence has been expanded to a proposal that assessing evidence is not a linear process, but is circular.<ref name="pmid16796762">{{cite journal |author=Walach H ''et al.'' |title=Circular instead of hierarchical: methodological principles for the evaluation of complex interventions |journal=BMC Med Res Methodol |volume=6 |pages=29 |year=2006 |pmid=16796762 |doi=10.1186/1471-2288-6-29}}</ref>


However such trials are very expensive, difficult to co-ordinate properly, and are often impractical to design optimally. For example, for many types of medical intervention, no satisfactory placebo treatment is possible. For several medical interventions, the use of a placebo, although feasible, is considered unethical (see section on [[#Unethical_use_of_placebos|Unethical use of placebos]]).
Diamond has proposed a method using Bayesian beliefs for assessing medical evidence that categorizes beliefs similarly to how evidence is assessed in the legal system.<ref name="pmid19667308">{{cite journal| author=Diamond GA, Kaul S| title=Bayesian classification of clinical practice guidelines. | journal=Arch Intern Med | year= 2009 | volume= 169 | issue= 15 | pages= 1431-5 | pmid=19667308
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=19667308 | doi=10.1001/archinternmed.2009.235 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


Sackett, one of the founders of evidence-based medicine, recognized that large-scale trials were not conducted for many conditions (see [[#Lack_of_randomized_controlled_trials_for_clinical_decisions|section below]]), and that it might not be possible to conduct them. Underlining the inherent difficulty in extrapolating from large scale trials, Sackett proposed the use of [[N of 1 randomized controlled trials]] (also called single-subject randomized trials). In these trials, the patient is both the treatment group and the placebo group, but at different time periods. Blinding must be done with the collaboration of the pharmacist, and treatment effects must appear and dissapear quickly following introduction and cessation of the therapy. This type of RCT can be performed for many chronic, stable conditions.<ref name="pmid3409138">{{cite journal |author=Guyatt G, Sackett D, Adachi J, ''et al'' |title=A clinician's guide for conducting randomized trials in individual patients |journal=CMAJ : Canadian Medical Association journal &#61; journal de l'Association medicale canadienne |volume=139 |issue=6 |pages=497–503 |year=1988 |pmid=3409138 |doi=}}</ref> The individualized nature of the single-subject randomized trial, and the fact that it often requires the active participation of the patient (questionnaires, diaries), appeals to the patient and promotes better insight and self-management<ref name="pmid17371593">{{cite journal |author=Brookes ST, Biddle L, Paterson C, Woolhead G, Dieppe P |title="Me's me and you's you": Exploring patients' perspectives of single patient (n-of-1) trials in the UK |journal=Trials |volume=8 |issue= |pages=10 |year=2007 |pmid=17371593 |doi=10.1186/1745-6215-8-10}}</ref><ref name="pmid8299295">{{cite journal |author=Langer JC, Winthrop AL, Issenman RM |title=The single-subject randomized trial. A useful clinical tool for assessing therapeutic efficacy in pediatric practice |journal=Clinical pediatrics |volume=32 |issue=11 |pages=654–7 |year=1993 |pmid=8299295 |doi=}}</ref> as well as patient safety,<ref name="pmid8616414">{{cite journal |author=Mahon J, Laupacis A, Donner A, Wood T |title=Randomised study of n of 1 trials versus standard practice |journal=BMJ |volume=312 |issue=7038 |pages=1069–74 |year=1996 |pmid=8616414 |doi=}}</ref> in a cost-effective manner.
=====The legal system=====
:See [[Medical malpractice#Standard of care]]


==Evidence synthesis: summarizing the evidence==
===Systematic review===
===Systematic review===
{{main|Systematic review}}
{{main|Systematic review}}
A systematic review is a summary of healthcare research that involves a thorough literature search and critical appraisal of individual studies to identify the valid and applicable evidence. It often, but not always, uses appropriate techniques ([[meta-analysis]]) to combine these valid studies, and may grade the quality of the particular pieces of evidence according to the methodology used, and according to strengths or weaknesses of thstudy design.
A systematic review is a summary of healthcare research that involves a thorough literature search and critical appraisal of individual studies to identify the valid and applicable evidence. It often, but not always, uses appropriate techniques ([[meta-analysis]]) to combine studies, and may grade the quality of the particular pieces of evidence according to the methodology used, and according to strengths or weaknesses of the study design. While many systematic reviews are based on an explicit [[quantitative research|quantitative]] [[meta-analysis]] of available data, there are also [[qualitative research|qualitative]] reviews which nonetheless adhere to the standards for gathering, analyzing and reporting evidence.
 
While many systematic reviews are based on an explicit [[quantitative research|quantitative]] [[meta-analysis]] of available data, there are also [[qualitative research|qualitative]] reviews which nonetheless adhere to the standards for gathering, analyzing and reporting evidence.


===Clinical practice guidelines===
===Clinical practice guidelines===
Line 126: Line 225:
Clinical practice guidelines are defined as "Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery."<ref>{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2007/MB_cgi?mode=&term=practice+guidelines |title=Clinical practice guidelines|author=National Library of Medicine |accessdate=2007-10-19 |format= |work=}}</ref>
Clinical practice guidelines are defined as "Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery."<ref>{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2007/MB_cgi?mode=&term=practice+guidelines |title=Clinical practice guidelines|author=National Library of Medicine |accessdate=2007-10-19 |format= |work=}}</ref>


==Medical informatics: Incorporating evidence into clinical care==
==Incorporating evidence into clinical care==
''see also [[Teaching evidence-based medicine]]''
===Medical informatics===
{{main|Medical informatics}}
{{main|Medical informatics}}
Practicing clinicians usually cite the lack of time for reading newer textbooks or journals. However, the emergence of new types of evidence can change the way doctors treat patients. Unfortunately the recent scientific evidence gathered through well controlled [[clinical trial]]s usually do not reach the busy clinicians in real time. Another potential problem lies in the fact that there may be numerous trials on similar interventions and outcomes but they are not [[systematic review|systematically reviewed]] or [[meta analysis|meta-analyzed]].
Practicing clinicians cite the lack of time for keeping up with emerging medical evidence that may change clinical practice.<ref name="pmid15647224">{{cite journal |author=Mendelson D, Carino TV |title=Evidence-based medicine in the United States--de rigueur or dream deferred? |journal=Health Affairs (Project Hope) |volume=24 |pages=133–6 |year=2005 |pmid=15647224 |doi=10.1377/hlthaff.24.1.133 |issn=}}</ref> [[Medical informatics]] is an essential adjunct to EBM, and focuses on creating tools to access and apply the best evidence for making decisions about patient care.<ref name="isbn0-443-07444-5"/> Before practicing EBM, informaticians (or informationists) must be familiar with medical [[academic journal|journals]], literature databases, medical textbooks, practice guidelines, and the growing number of other evidence-based resources, like the Cochrane Database of Systematic Reviews and Clinical Evidence.<ref name="pmid15647224">{{cite journal |author=Mendelson D, Carino TV |title=Evidence-based medicine in the United States--de rigueur or dream deferred? |journal=Health Affairs (Project Hope) |volume=24 |pages=133–6 |year=2005 |pmid=15647224 |doi=10.1377/hlthaff.24.1.133 |issn=}}</ref> Similarly, for practicing medical informatics properly, it is essential to have an understanding of EBM, including the ability to phrase an answerable question, locate and retrieve the best evidence, and critically appraise and apply it.<ref name="pmid11838463">{{cite journal |author=Hersh W |title=Medical informatics education: an alternative pathway for training informationists |journal=JMLA |volume=90 |pages=76–9 |year=2002 |pmid=11838463 |doi= |issn=}}</ref><ref name="pmid11838456">{{cite journal |author=Shearer BS ''et al.'' |title=Bringing the best of medical librarianship to the patient team |journal=JMLA |volume=90 |pages=22–31 |year=2002 |pmid=11838456 |doi= |issn=}}</ref>
 
[[Medical informatics]] is an essential adjunct to EBM, and focuses on creating tools to access and apply the best evidence for making decisions about patient care.<ref name="isbn0-443-07444-5"/>
 
Before practicing EBM, informaticians (or informationists) must be familiar with medical journals, literature databases, medical textbooks, practice guidelines, and the growing number of other dedicated evidence-based resources, like the Cochrane Database of Systematic Reviews and Clinical Evidence.<ref name="pmid15647224">{{cite journal |author=Mendelson D, Carino TV |title=Evidence-based medicine in the United States--de rigueur or dream deferred? |journal=Health Affairs (Project Hope) |volume=24 |pages=133–6 |year=2005 |pmid=15647224 |doi=10.1377/hlthaff.24.1.133 |issn=}}</ref>


Similarly, for practicing medical informatics properly, it is essential to have an understanding of EBM, including the ability to phrase an answerable question, locate and retrieve the best evidence, and critically appraise and apply it.<ref name="pmid11838463">{{cite journal |author=Hersh W |title=Medical informatics education: an alternative pathway for training informationists |journal=JMLA |volume=90 |pages=76–9 |year=2002 |pmid=11838463 |doi= |issn=}}</ref><ref name="pmid11838456">{{cite journal |author=Shearer BS ''et al.'' |title=Bringing the best of medical librarianship to the patient team |journal=JMLA |volume=90 |pages=22–31 |year=2002 |pmid=11838456 |doi= |issn=}}</ref>
===Health care quality assurance===
{{main|Health care quality assurance}}
==Criticisms of EBM==
[[Image:Hume.jpg|thumb|right|Statue of [[David Hume]]. ''"Man is a reasonable being; and as such, receives from science his proper food and nourishment: But so narrow are the bounds of human understanding, that little satisfaction can be hoped for in this particular..."''
[[David Hume|Hume]] recognised clearly the difficulties in gaining a general understanding merely by accumulating observations.]]


There are a number of criticisms of EBM.<ref name="pmid17264255">{{cite journal |author=Straus S ''et al.'' |title=Misunderstandings, misperceptions, and mistakes |journal=Evidence-based medicine |volume=12 |pages=2–3 |year=2007 |pmid=17264255 |doi=10.1136/ebm.12.1.2-a}}</ref><ref name="pmid11033714">{{cite journal |author=Straus SE, McAlister FA |title=Evidence-based medicine: a commentary on common criticisms |journal=CMAJ |volume=163  |pages=837–41 |year=2000 |pmid=11033714 |doi=}}</ref>


===Excessive reliance on empiricism and deduction===
EBM has been criticized as an attempt to define knowledge in medicine in the same way that was done unsuccessfully by the logical positivists in epistemology, "trying to establish a secure foundation for scientific knowledge based only on observed facts" <ref name="pmid12204023">{{cite journal |author=Goodman SN |title=The mammography dilemma: a crisis for evidence-based medicine? |journal=Ann Intern Med |volume=137  |pages=363–5 |year=2002 |pmid=12204023 |doi=|url=http://www.annals.org/cgi/content/full/137/5_Part_1/363}}</ref>and not recognizing the fallible nature of knowledge in general.<ref name="pmid10970003">{{cite journal |author=Upshur RE |title=Seven characteristics of medical evidence |journal=J Eval Clin Pract |volume=6  |pages=93–7 |year=2000 |pmid=10970003 |doi= |issn=}}</ref> The problem of relying on empiric evidence as a foundation for knowledge was recognized over 100 years ago and is known as the "Problem of Induction" or "[[David Hume|Hume]]'s Problem".<ref>{{cite web |url=http://plato.stanford.edu/entries/induction-problem/ |title=The Problem of Induction (Stanford Encyclopedia of Philosophy) |accessdate=2007-11-16 |author=Vickers, J |authorlink= |coauthors= |date=2006 |format= |work= |publisher=Stanford Encyclopedia of Philosophy |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> Alternative [[logic]] is induction and abduction.<ref name="pmid16373725">{{cite journal| author=Rapezzi C, Ferrari R, Branzi A| title=White coats and fingerprints: diagnostic reasoning in medicine and investigative methods of fictional detectives. | journal=BMJ | year= 2005 | volume= 331 | issue= 7531 | pages= 1491-4 | pmid=16373725
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16373725 | doi=10.1136/bmj.331.7531.1491 | pmc=PMC1322237 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


 
===Inability to individualize for each patient===
 
==Criticisms of evidence-based medicine==
There are a number of criticisms of EBM.<ref name="pmid17264255">{{cite journal |author=Straus S ''et al.'' |title=Misunderstandings, misperceptions, and mistakes |journal=Evidence-based medicine |volume=12 |issue=1 |pages=2–3 |year=2007 |pmid=17264255 |doi=10.1136/ebm.12.1.2-a}}</ref><ref name="pmid11033714">{{cite journal |author=Straus SE, McAlister FA |title=Evidence-based medicine: a commentary on common criticisms |journal=CMAJ : Canadian Medical Association journal |volume=163  |pages=837–41 |year=2000 |pmid=11033714 |doi=}}</ref> Most generally, EBM has been criticized as an attempt to define knowledge in medicine in the same way that was done unsuccessfully by the logical positivists in epistemology, "trying to establish a secure foundation for scientific knowledge based only on observed facts".<ref name="pmid12204023">{{cite journal |author=Goodman SN |title=The mammography dilemma: a crisis for evidence-based medicine? |journal=Ann Intern Med |volume=137  |pages=363–5 |year=2002 |pmid=12204023 |doi=|url=http://www.annals.org/cgi/content/full/137/5_Part_1/363}}</ref>
 
A general problem with EBM is that it seeks to make recommendations for treatment that (on balance) are likely to provide the best treatment for most patients. However what is the best treatment for most patients is not necessarily the best treatment for a particular individual patient. The causes of disease, and the patient responses to treatment all vary considerably, and are affected for example by the individual's genetic make-up, their particular history, and by factors of individual lifestyle. To take these properly into account requires the clinical experience of the treating physician, and over-reliance upon recommendations based upon statistical outcomes of treatments given in a standardised way to large populations may not always lead to the best care for a particular individual.
A general problem with EBM is that it seeks to make recommendations for treatment that (on balance) are likely to provide the best treatment for most patients. However what is the best treatment for most patients is not necessarily the best treatment for a particular individual patient. The causes of disease, and the patient responses to treatment all vary considerably, and are affected for example by the individual's genetic make-up, their particular history, and by factors of individual lifestyle. To take these properly into account requires the clinical experience of the treating physician, and over-reliance upon recommendations based upon statistical outcomes of treatments given in a standardised way to large populations may not always lead to the best care for a particular individual.
===Unethical use of placebos===
Ideally, the true effectiveness of any medical treatment should be compared with the effectiveness of a placebo treatment in a double-blind trial, where neither the patient nor the doctor is aware of whether the treatment administered is an active treatment or an inert placebo. Placebo controls are thought to be very important because of the very considerable "power of suggestion". However, as stated in The [[Declaration of Helsinki]] by the [[World Medical Association]] it is unethical to give any patient a placebo treatment if an existing treatment option is known to be beneficial.<ref>{{cite web |url=http://www.wma.net/e/policy/b3.htm |title=Declaration of Helsinki: Ethical Principles for Medical Research Involving Human                      Subjects |author=World Medical Association|accessdate=2007-11-17 |format= |work=}}</ref><ref name="pmid9062334">{{cite journal |author= |title=World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects |journal=JAMA |volume=277 |pages=925–6 |year=1997 |pmid=9062334 |doi=}}</ref> Many scientists and ethicists consider that the U.S. [[Food and Drug Administration]], by demanding placebo-controlled trials, encourages the systematic violation of the Declaration of Helsinki.<ref name="pmid12812185">{{cite journal |author=Michels KB, Rothman KJ |title=Update on unethical use of placebos in randomised trials |journal=Bioethics |volume=17  |pages=188–204 |year=2003 |pmid=12812185 |doi=}}</ref> The use of placebo controls remains a convenient way to avoid direct comparisons with a competing drug.
As EBM evolves, appropriate use of placebo is being revised.<ref name="pmid10975964">{{cite journal |author=Temple R, Ellenberg SS |title=Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues |journal=Ann Intern Med |volume=133 |pages=455–63 |year=2000 |pmid=10975964 |doi=|url=http://www.annals.org/cgi/content/full/133/6/455}}</ref><ref name="pmid10975965">{{cite journal |author=Ellenberg SS, Temple R |title=Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases |journal=Ann Intern Med |volume=133  |pages=464–70 |year=2000 |pmid=10975965 |doi=|url=http://www.annals.org/cgi/content/full/133/6/464}}</ref> When guidelines suggest a placebo is an unethical control, then an "active-control noninferiority trial" may be  used.<ref name="pmid16818930">{{cite journal |author=Kaul S, Diamond GA |title=Good enough: a primer on the analysis and interpretation of noninferiority trials |journal=Ann Intern Med |volume=145 |pages=62–9 |year=2006 |pmid=16818930 |doi=|url=http://www.annals.org/cgi/content/full/145/1/62}}</ref> To establish non-inferiority, the following three conditions should be - but frequently are not - established:<ref name="pmid16818930"/>
# "The treatment under consideration exhibits therapeutic noninferiority to the active control."
# "The treatment would exhibit therapeutic efficacy in a placebo-controlled trial if such a trial were to be performed."
# "The treatment offers ancillary advantages in safety, tolerability, cost, or convenience."
===Lack of randomized controlled trials for clinical decisions===
[[Randomized controlled trial]]s are available to support 21%<ref name="pmid9701101">{{cite journal |author=Michaud G ''et al.'' |title=Are therapeutic decisions supported by evidence from health care research? |journal=Arch Intern Med |volume=158 |pages=1665–8 |year=1998 |pmid=9701101 |doi=}}</ref> to 53%<ref name="pmid7623571">{{cite journal |author=Ellis J ''et al.''|title=Inpatient general medicine is evidence based. A-Team, Nuffield Department of Clinical Medicine |journal=Lancet |volume=346  |pages=407–10 |year=1995 |pmid=7623571 |doi=}}</ref> of principle therapeutic decisions.<ref>{{cite web |url=http://www.shef.ac.uk/scharr/ir/percent.html |title=Percentage of practice that is evidence based? |accessdate=2007-11-15 |author=Booth, A |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> Due to this, evidence-based medicine has evolved to accept lesser levels of evidence when randomized controlled trials are not available.<ref name="pmid17213159">{{cite journal |author=Haynes RB |title=Of studies, syntheses, synopses, summaries, and systems: the "5S" evolution of information services for evidence-based healthcare decisions |journal=Evidence-based Medicine |volume=11  |pages=162–4 |year=2006 |pmid=17213159 |doi=10.1136/ebm.11.6.162-a}}</ref>


===Ulterior motives===
===Ulterior motives===
An early criticism of EBM is that it will be a guise for rationing resources or other goals that are not in the interest of the patient.<ref name="pmid7742683">{{cite journal |author=Grahame-Smith D |title=Evidence based medicine: Socratic dissent |journal=BMJ |volume=310 |pages=1126–7 |year=1995 |pmid=7742683 |doi=|url=http://www.bmj.com/cgi/content/full/310/6987/1126}}</ref><ref name="pmid11525707">{{cite journal |author=Formoso G ''et al.'' |title=Practice guidelines: useful and "participative" method? Survey of Italian physicians by professional setting |journal=Arch Intern Med |volume=161 |pages=2037–42 |year=2001 |pmid=11525707 |doi=}}</ref> In 1994, the [[American Medical Association]] helped introduce the "Patient Protection Act" in Congress to reduce the power of insurers to use guidelines to deny payment for a medical services.<ref>{{cite web |url=http://query.nytimes.com/gst/fullpage.html?res=9B0DE1DC1E38F937A15756C0A962958260&sec=&spon=&partner=permalink&exprod=permalink |title=A.M.A. and Insurers Clash Over Restrictions on Doctors - New York Times |author=Pear, R|accessdate=2007-11-14 |format= |work=}}</ref>
An early criticism of EBM is that it will be a guise for rationing resources or other goals that are not in the interest of the patient.<ref name="pmid7742683">{{cite journal |author=Grahame-Smith D |title=Evidence based medicine: Socratic dissent |journal=BMJ |volume=310 |pages=1126–7 |year=1995 |pmid=7742683 |doi=|url=http://www.bmj.com/cgi/content/full/310/6987/1126}}</ref><ref name="pmid11525707">{{cite journal |author=Formoso G ''et al.'' |title=Practice guidelines: useful and "participative" method? Survey of Italian physicians by professional setting |journal=Arch Intern Med |volume=161 |pages=2037–42 |year=2001 |pmid=11525707 |doi=}}</ref> In 1994, the [[American Medical Association]] helped introduce the "Patient Protection Act" in Congress to reduce the power of insurers to use guidelines to deny payment for a medical services.<ref>{{cite web |url=http://query.nytimes.com/gst/fullpage.html?res=9B0DE1DC1E38F937A15756C0A962958260&sec=&spon=&partner=permalink&exprod=permalink |title=A.M.A. and Insurers Clash Over Restrictions on Doctors - New York Times |author=Pear, R|accessdate=2007-11-14 |format= |work=}}</ref> As a possible example, Milliman Care Guidelines state they produce "evidence-based clinical guidelines since 1990".<ref>{{cite web |url=http://www.careguidelines.com/company/ |title=Evidence-Based Clinical Guidelines by Milliman Care Guidelines |accessdate=2007-11-14 |format= |work=}}</ref> In 2000, an academic pediatrician sued Milliman for using his name as an author on a practice guidelines that he stated were "dangerous" <ref>{{cite web |url=http://www.chron.com/CDA/archives/archive.mpl?id=2000_3199375 |title=Cost-cutting guide used by HMOs called `dangerous' / Doctor on UT-Houston Medical School staff sues publisher |author=Nissimov, R|publisher=Houston Chronicle|year=2000|accessdate=2007-11-14 |format= |work=}}</ref><ref>{{cite web |url=http://www.chron.com/CDA/archives/archive.mpl?id=2000_3254627 |title=Judge tells firm to explain how pediatric rules derived |author=Nissimov, R|year=2000|accessdate=2007-11-14 |format= |work=|publisher= Houston Chronicle}}</ref><ref>{{cite web |url=http://www.wsj.com |title=Insurance Health-Care Guidelines Are Assailed for Putting Patients Last |author=Martinez, B|year=2000|publisher=Wall Street Journal|format= |work=}}</ref> A similar suit disputing the origin of care decisions at Kaiser has been filed.<ref>{{cite web |url=http://www.sfgate.com/cgi-bin/article.cgi?file=/chronicle/archive/2002/01/07/BU178030.DTL&type=business |title=Lawsuit disputes truth of Kaiser Permanente ads |accessdate=2007-11-14 |author=Colliver, V |authorlink= |coauthors= |date=1/07/2002|year=2002 |format= |work= |publisher=San Francisco Chronicle |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> The outcomes of both suits are not known.
 
As a possible example, Milliman Care Guidelines state they produce "evidence-based clinical guidelines since 1990".<ref>{{cite web |url=http://www.careguidelines.com/company/ |title=Evidence-Based Clinical Guidelines by Milliman Care Guidelines |accessdate=2007-11-14 |format= |work=}}</ref> In 2000, an academic pediatrician sued Milliman for using his name as an author on a practice guidelines that he stated were "dangerous" <ref>{{cite web |url=http://www.chron.com/CDA/archives/archive.mpl?id=2000_3199375 |title=Cost-cutting guide used by HMOs called `dangerous' / Doctor on UT-Houston Medical School staff sues publisher |author=Nissimov, R|publisher=Houston Chronicle|year=2000|accessdate=2007-11-14 |format= |work=}}</ref><ref>{{cite web |url=http://www.chron.com/CDA/archives/archive.mpl?id=2000_3254627 |title=Judge tells firm to explain how pediatric rules derived |author=Nissimov, R|year=2000|accessdate=2007-11-14 |format= |work=|publisher= Houston Chronicle}}</ref><ref>{{cite web |url=http://www.wsj.com |title=Insurance Health-Care Guidelines Are Assailed for Putting Patients Last |author=Martinez, B|year=2000|publisher=Wall Street Journal|format= |work=}}</ref> A similar suit disputing the origin of care decisions at Kaiser has been filed.<ref>{{cite web |url=http://www.sfgate.com/cgi-bin/article.cgi?file=/chronicle/archive/2002/01/07/BU178030.DTL&type=business |title=Lawsuit disputes truth of Kaiser Permanente ads |accessdate=2007-11-14 |author=Colliver, V |authorlink= |coauthors= |date=1/07/2002|year=2002 |format= |work= |publisher=San Francisco Chronicle |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> The outcomes of both suits are not known.


Conversely, [[clinical practice guideline]]s by the [[Infectious Disease Society of America]] are being investigated by Connecticut's attorney general on grounds that the guidelines, which do not recognize a chronic form of Lyme disease, are anticompetitive.<ref>{{cite web |url=http://www.the-scientist.com/news/print/49605/ |title=The Scientist : State official subpoenas infectious disease group|author=Warner, S |accessdate=2007-11-14|date=2/7/2007|year=2007 |format= |work=}}</ref><ref>{{cite web |url=http://www.acponline.org/journals/news/jan-feb07/lyme.htm |title=ACP Observer, January-February 2007 - Experts spar over treatment for 'chronic' Lyme disease|author=Gesensway, D|year=2007 |accessdate=2007-11-14 |format= |work=}}</ref>
Conversely, [[clinical practice guideline]]s by the [[Infectious Disease Society of America]] are being investigated by Connecticut's attorney general on grounds that the guidelines, which do not recognize a chronic form of Lyme disease, are anticompetitive.<ref>{{cite web |url=http://www.the-scientist.com/news/print/49605/ |title=The Scientist : State official subpoenas infectious disease group|author=Warner, S |accessdate=2007-11-14|date=2/7/2007|year=2007 |format= |work=}}</ref><ref>{{cite web |url=http://www.acponline.org/journals/news/jan-feb07/lyme.htm |title=ACP Observer, January-February 2007 - Experts spar over treatment for 'chronic' Lyme disease|author=Gesensway, D|year=2007 |accessdate=2007-11-14 |format= |work=}}</ref>


===EBM not recognizing the limits of clinical epidemiology===
===EBM not recognizing the limits of clinical epidemiology===
EBM is a set of techniques derived from clinical epidemiology, but a common criticism of epidemiology is that it can show association, but not causation.  While clinical epidemiology has its role in inspiring clinical decisions, if it is complemented with testable hypotheses on disease,<ref name="pmid-10970004">{{cite journal |author=Djulbegovic B ''et al.''|title=Evidentiary challenges to evidence-based medicine |journal=Journal of evaluation in clinical practice |volume=6 |pages=99–109 |year=2000 |pmid=10970004 |doi= |issn=}}</ref> many critics consider that EBM is a form of clinical epidemiology which became so prevalent in health care systems, and imposed such an empiricist bias on medical research, that it has undermined the very notion of causal inference in clinical practice.<ref>Charlton BG. [Book Review: Evidence-based medicine: how to practice and teach EBM by Sackett DL, Richardson WS, Rosenberg W, Haynes RB. http://www.hedweb.com/bgcharlton/journalism/ebm.html] Journal of Evaluation in Clinical Practice. 1997; 3:169-172</ref> It is argued that it has even become condemnable to use common sense,<ref name="pmid15189382">{{cite journal |author=Michelson J |title=Critique of (im)pure reason: evidence-based medicine and common sense |journal=Journal of evaluation in clinical practice |volume=10 |issue=2 |pages=157–61 |year=2004 |pmid=15189382 |doi=10.1111/j.1365-2753.2003.00478.x}}</ref> as was cleverly illustrated in a systematic review of randomized controlled trials studying the effects of parachutes against gravitational challenges (free falls).<ref name="pmid14684649">{{cite journal |author=Smith GC, Pell JP |title=Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials |journal=BMJ |volume=327  |pages=1459–61 |year=2003 |pmid=14684649 |doi=10.1136/bmj.327.7429.1459 |issn=}}</ref>
EBM is a set of techniques derived from clinical epidemiology, but a common criticism is that epidemiology can show ''association'' but not ''causation''.  While clinical epidemiology has its role in inspiring clinical decisions if it is complemented with testable hypotheses on disease,<ref name="pmid-10970004">{{cite journal |author=Djulbegovic B ''et al.''|title=Evidentiary challenges to evidence-based medicine |journal=Journal of evaluation in clinical practice |volume=6 |pages=99–109 |year=2000 |pmid=10970004 |doi= |issn=}}</ref> many critics consider that EBM is a form of clinical epidemiology which became so common in health care systems, and imposed such an empiricist bias on medical research, that it has undermined the notion of causal inference in clinical practice.<ref>Charlton BG. [Book Review: Evidence-based medicine: how to practice and teach EBM by Sackett DL, Richardson WS, Rosenberg W, Haynes RB. http://www.hedweb.com/bgcharlton/journalism/ebm.html] Journal of Evaluation in Clinical Practice. 1997; 3:169-172</ref> It is argued that it has even become condemnable to use common sense,<ref name="pmid15189382">{{cite journal |author=Michelson J |title=Critique of (im)pure reason: evidence-based medicine and common sense |journal=J Evaluation Clin Pract|volume=10 |pages=157–61 |year=2004 |pmid=15189382 |doi=10.1111/j.1365-2753.2003.00478.x}}</ref> as was cleverly illustrated in a systematic review of randomized controlled trials studying the effects of parachutes against gravitational challenges (free falls).<ref name="pmid14684649">{{cite journal |author=Smith GC, Pell JP |title=Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials |journal=BMJ |volume=327  |pages=1459–61 |year=2003 |pmid=14684649 |doi=10.1136/bmj.327.7429.1459 |issn=}}</ref>
 
===Fallibility of knowledge===
[[Image:Hume.jpg|thumb|right|Statue of David Hume. ''"Man is a reasonable being; and as such, receives from science his proper food and nourishment: But so narrow are the bounds of human understanding, that little satisfaction can be hoped for in this particular..."''
Hume recognised clearly the difficulties in gaining a general understanding merely by gathering evidence.]]EBM has been criticized on epistemologic grounds as "trying to establish a secure foundation for scientific knowledge based only on observed facts"<ref name="pmid12204023">{{cite journal |author=Goodman SN |title=The mammography dilemma: a crisis for evidence-based medicine? |journal=Ann. Intern. Med. |volume=137 |issue=5 Part 1 |pages=363–5 |year=2002 |pmid=12204023 |doi= |issn=}}</ref> and not recognizing the fallible nature<ref name="pmid10970003">{{cite journal |author=Upshur RE |title=Seven characteristics of medical evidence |journal=Journal of evaluation in clinical practice |volume=6 |issue=2 |pages=93–7 |year=2000 |pmid=10970003 |doi= |issn=}}</ref> of knowledge in general. The inevitable failure of reliance on empiric evidence as a foundation for knowledge was recognized over 100 years ago and is known as the "Problem of Induction" or "Hume's Problem".<ref>{{cite web |url=http://plato.stanford.edu/entries/induction-problem/ |title=The Problem of Induction (Stanford Encyclopedia of Philosophy) |accessdate=2007-11-16 |author=Vickers, J |authorlink= |coauthors= |date=2006 |format= |work= |publisher=Stanford Encyclopedia of Philosophy |pages= |language= |archiveurl= |archivedate= |quote=}}</ref>


====Complexity theory====
[[Image:Lorenz butterfly.jpg|160px|right|thumb|Lorenz butterfly showing two attractors in a complex, chaotic system. See [[complexity science]].]]
[[Complexity theory]] and chaos theory are proposed as further explaining the nature of medical knowledge.<ref name="isbn1-85775-724-6">{{cite book |author=Sweeney, Kieran  |title=Complexity in Primary Care: Understanding Its Value |publisher=Radcliffe Medical Press |location=Abingdon |year=2006 |pages= |isbn=1-85775-724-6 |oclc= |doi=}}[http://www.acpjc.org/Content/147/3/issue/ACPJC-2007-147-3-A11.htm Review]</ref><ref name="isbn1-85775-855-2">{{cite book |author=Holt, Tim A | title=Complexity for Clinicians |publisher=Radcliffe Medical Press |location=Abingdon |year=2004 |pages= |isbn=1-85775-855-2 |oclc= |doi=}} [http://www.mja.com.au/public/bookroom/2007/zwar/zwar.html Review], [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1463117 ACP Journal Club Review]</ref> Regarding health services research, although complexity theory has not advanced to the state of being able to mathematically model healthcare delivery, it has been used as a framework for case study<ref name="pmid-15802542">{{cite journal |author=Anderson RA, Crabtree BF, Steele DJ, McDaniel RR |title=Case study research: the view from complexity science |journal=Qualitative health research |volume=15 |issue=5 |pages=669–85 |year=2005 |pmid=15802542 |doi=10.1177/1049732305275208}}</ref><ref name="pmid-11674890">{{cite journal |author=Miller WL, McDaniel RR, Crabtree BF, Stange KC |title=Practice jazz: understanding variation in family practices using complexity science |journal=The Journal of family practice |volume=50 |issue=10 |pages=872–8 |year=2001 |pmid=11674890 |doi=|url=http://www.jfponline.com/Pages.asp?AID=2354&issue=October%202001}}</ref><ref name="pmid-11674891">{{cite journal |author=Crabtree BF ''et al.'' |title=Understanding practice from the ground up |journal=The Journal of Family Practice |volume=50 |pages=881–7 |year=2001 |pmid=11674891 |doi=|url=http://www.jfponline.com/Pages.asp?AID=2355&issue=October%202001}}</ref><ref name="pmid-17339983">{{cite journal |author=Sturmberg JP |title=Systems and complexity thinking in general practice: part 1 - clinical application |journal=Australian family physician |volume=36 |pages=170–3 |year=2007 |pmid=17339983 |doi=}}</ref> and traditional bivariate analysis<ref name="pmid-17725834">{{cite journal |author=Leykum LK ''et al.'' |title=Organizational interventions employing principles of complexity science have improved outcomes for patients with Type II diabetes |journal=Implementation science : IS |volume=2  |pages=28 |year=2007 |pmid=17725834 |doi=10.1186/1748-5908-2-28}}</ref> of healthcare delivery. For example, a [[systematic review]] of organizational interventions to improve the quality of care of [[diabetes mellitus type 2]] suggests that interventions based on complexity theory will be more successful.<ref name="pmid-17725834"/> If the goal of modeling healthcare is to comply with specific quality indicators, interventions based on systems theory may be more effective than those based on complexity theory.<ref name="pmid-15175493">{{cite journal |author=Rhydderch M ''et al.'' |title=Organisational change theory and the use of indicators in general practice |journal=Quality & Safety in Health Care |volume=13 |pages=213–7 |year=2004 |pmid=15175493 |doi=10.1136/qhc.13.3.213}}</ref>
===Complexity science===
{{main|complexity science}}
[[Complexity science]] and chaos theory are proposed as further explaining the nature of medical knowledge<ref name="isbn1-85775-724-6">{{cite book |author=Sweeney, Kieran  |title=Complexity in Primary Care: Understanding Its Value |publisher=Radcliffe Medical Press |location=Abingdon |year=2006 |pages= |isbn=1-85775-724-6 |oclc= |doi=}}[http://www.acpjc.org/Content/147/3/issue/ACPJC-2007-147-3-A11.htm Book review]</ref><ref name="isbn1-85775-855-2">{{cite book |author=Holt, Tim A | title=Complexity for Clinicians |publisher=Radcliffe Medical Press |location=Abingdon |year=2004 |pages= |isbn=1-85775-855-2 |oclc= |doi=}} [http://www.mja.com.au/public/bookroom/2007/zwar/zwar.html Book review], [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1463117 ACP Journal Club Review]</ref> and education<ref name="pmid11588088">{{cite journal |author=Fraser SW, Greenhalgh T |title=Coping with complexity: educating for capability |journal=BMJ |volume=323 |issue=7316 |pages=799–803 |year=2001 |pmid=11588088 |doi=}}</ref>.


==References==
==Footnotes==
<references/>
<small>
<references>


==See also==
</references>
* [[Teaching evidence-based medicine]]
</small>
* [[Evidence-based individual decision making]]

Latest revision as of 06:54, 10 October 2024

This article has a Citable Version.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article has an approved citable version (see its Citable Version subpage). While we have done conscientious work, we cannot guarantee that this Main Article, or its citable version, is wholly free of mistakes. By helping to improve this editable Main Article, you will help the process of generating a new, improved citable version.

Evidence-based medicine is "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients."[1] Alternative definitions are "the process of systematically finding, appraising, and using contemporaneous research findings as the basis for clinical decisions"[2] or "evidence-based medicine (EBM) requires the integration of the best research evidence with our clinical expertise and our patient's unique values and circumstances."[3] Better known as EBM, evidence based medicine has roots in clinical epidemiology and the scientific method, and emerged in the early 1990's in response to discoveries about variations and deficiencies[4] in medical care to help healthcare providers and policy makers evaluate the efficacy of different treatments.

Evidence-based practice is not restricted to medicine: dentistry, nursing and other allied health science are adopting "evidence-based medicine" as well as alternative medical approaches, such as acupuncture[5][6]. Evidence-Based Health Care or evidence-based practice extends the concept of EBM to all health professions, including management[7][8] and policy[9][10][11].

Classification

Two types of evidence-based medicine have been proposed:[12]

  • Evidence-based guidelines, EBM at the organizational or institutional level, which involves producing clinical practice guidelines, policy, and regulations;

Justification

Part of the justification for EBM is the unreliability about making clinical decisions using heuristics.[13][14]

Steps in EBM

See also Teaching evidence-based medicine
The 5 S search strategy[15]

Studies: original research studies that can be found using search engines like PubMed.

Synthesis: systematic reviews or Cochrane Reviews.

Synopses: in EBM journals, ACP Journal club etc. give brief descriptions of original articles and reviews as they appear .

Summaries: in EBM textbooks integrate the best available evidence from syntheses to give evidence-based management options for a health problem.

Systems: e.g. computerized decision support systems that link individual patient characteristics to relevant evidence.

Ask

To "ask" and formulate a well-structured clinical question, i.e. one that is directly relevant to the identified problem, and which is constructed in a way that facilitates searching for an answer. The question should have four 'PICO' elements[16][17]: the patient or problem (P); the medical intervention or exposure (e.g., a cause for a disease) (I); the comparison intervention or exposure (C); and the clinical outcomes (O). The better focused the question is, the more relevant and specific the search for evidence will be.[18]

Acquisition of evidence

Acquisition is difficult due to instability of medical knowledge[19][20][21][22][23][24]
Type of publication Durability
Primary publications
Highly cited studies major scientific journals[19] The results from one-third are refuted or attenuated within 15 years.
Original studies in hepatology[20] Half-life of truth was 45 years
Original studies in surgery[21] Half-life of truth was 45 years
Secondary publications
Systematic reviews[22] Median survival is 5.5 years.
7% may out of date when published
23% may be out of date within 2 years
Practice guidelines by the AHRQ[23] Half-life of truth was 5.8 years
Food and Drug Administration New Drug Approvals[24] 8% acquire a new black box warning. Half occur within 7 years
Food and Drug Administration New Drug Approvals[24] 3% withdrawn. Half occur within 2 years

The ability to "acquire" evidence, also called information retrieval, in a timely manner may improve healthcare.[25][26] Unfortunately, doctors may be led astray when acquiring information because of difficulties in selecting best articles[27], or because individual trials may be flawed or their outcomes may not be fully representative.[28]

Research conflicts on the ability of end-users of MEDLINE. One study found that users were almost as likely to misinterpret articles found as correctly interpret them.[28] A second study that was in vitro found that searching for evidence was helpful.[29]

One proposed structure for a comprehensive evidence search is the 5S search strategy,[15] and 6S[30] which starts with the search of "summaries" (textbooks). [31]

Appraisal of evidence

The U.S. Preventive Services Task Force (USPSTF) [32] grades its recommendations for treatments according to the strength of the evidence and the expected overall benefit (benefits minus harms). Its grades are:

A.— Good evidence that the treatment improves health outcomes, and benefits substantially outweigh harms.

B.— Fair evidence that the treatment improves health outcomes and that benefits outweigh harms.

C.— Fair evidence that the treatment can improve health outcomes but the balance of benefits and harms is too close to justify a general recommendation.

D.— Recommendation against routinely providing the treatment to asymptomatic patients. There is fair evidence that [the service] is ineffective or that harms outweigh benefits.

I.— The evidence is insufficient to recommend for or against routinely providing [the service]. Evidence that the treatment is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined.

The USPSTF also grades the quality of the overall evidence as good, fair or poor:

Good: Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health.

Fair: Evidence is sufficient to determine effects on health outcomes, but its strength is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes.

Poor: Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.

To "Appraise" the quality of the evidence in a study is very important, as one third of the results of even the most visible medical research is eventually either attenuated or refuted.[19] There are many reasons for this[33]; two of the most common being publication bias[34] and conflict of interest[35] (see article on Medical ethics). These two problems interact, as conflict of interest often leads to publication bias.[36][34] Complicating the appraisal process further, many (if not all) studies contain some design flaws, and even when there are no clear methodological flaws, any outcome of a test that is evaluated by statistical test has a margin of error: this means that some positive outcomes will be "false positives".

Often, only the abstract of an article will be read,[37] but many abstracts contain errors.[38] These are usually errors of omission rather than contradiction, but abstracts often over-emphasise positive findings and neglect to mention limitations.

When abstracts are read, readers may be biased [39] and make illogical conclusions[40].

The initial steps in reading an article are determining what the article's conclusion and whether its conclusion, if valid, is important.[41]

Overall risk in the population in a study can be assessed by examining outcome rr prevalence rates in the control groups.[42]

Automated text mining can help assess the quality of an article.[43]

"Levels of evidence" are used for describing the strength of a research study.[44][45] The Equator network is a collection of standards to improve the reporting of health research. An example is the Consort statement for the reporting of randomized controlled trials.

Guides exist for assessing a body of literature; these are discussed below, Assessing a body of research evidence.

Common threats to validity

Publication bias
Publication bias is "the influence of study results on the chances of publication [in academic journals] and the tendency of investigators, reviewers, and editors to submit or accept manuscripts for publication based on the direction or strength of the study findings. Publication bias has an impact on the interpretation of clinical trials and meta-analyses. Bias can be minimized by insistence by editors on high-quality research, thorough literature reviews, acknowledgment of conflicts of interest, modification of peer review practices, etc."[46]

Conflict of interest

For more information, see: Conflict of interest.

The presence of a conflict of interest has many effects in medical publishing.

Statistical analysis
Common problems include small sample sizes in subgroup analyses[47], problems of "multiple comparisons" when several outcomes are being assessed, and biasing of study populations by selection criteria.

Problems may arise from interim analyses of randomized controlled trials which may lead to exaggerated estimations of treatment effects.[48][49] [50]

Statistical significance:
The statistical significance of the outcome of a study is often summarized by a "P-value" that expresses the likelihood that an observed difference between treatment groups reflects a true difference in treatment effect; the P value is a calculation of the chance that the observed difference reflects the chance outcome of random sampling. Some have argued that focusing on P values neglects other important sources of knowledge and information that should be used to assess the likely efficacy of a treatment [51] In particular, some argue that the P-value should be interpreted in light of how plausible is the hypothesis based on the totality of prior research and physiologic knowledge.[52][51][53] Bayesian inference formalizes this approach to statistical significance.

Application

It is important to "apply" the best practices found to the correct situation. One common problem in applying evidence is that both patients and healthcare professionals often have difficulties with health numeracy and probabilistic reasoning.[54] Another problem is successful clinical reasoning at the bedside.[55] Successful reasoning is associated with the use of pattern matching [56][57] and recognizing clinical findings that are "pivot" or specific to certain diseases[57]. A third problem is to identify exactly which patients will benefit from the new practices. Extrapolating study results to the wrong patient populations (over-generalization)[58][59][60] and not applying study results to the correct population (under-utilization)[61][62] can both increase adverse outcomes.

The problem of over-generalizating study results may be more common among specialist physicians.[63] Two studies found specialists were more likely to adopt cyclooxygenase 2 inhibitor drugs before the drug rofecoxib was withdrawn by its manufacturers because of its unanticipated adverse effects [64][65]. One of the studies went on to state:

"using COX-2s as a model for physician adoption of new therapeutic agents, specialists were more likely to use these new medications for patients likely to benefit but were also significantly more likely to use them for patients without a clear indication".[65]

Similarly, orthopedists provide more expensive care for back pain, but without measurably increased benefit compared to other types of practitioners.[66] Some of the reason that subspecialists may be more likely to adopt inadequately studied innovations is that they read from a spectrum of journals that have less consistent quality.[67] Articles from specialty journals have been noted to persist in supporting claims in the medical literature that have been refuted.[68]

The problem of under-utilizing study results may be more common when physicians are practising outside their expertise. For example, specialist physicians are less likely to under-utilize specialty care[69][70], while primary care physicians are less likely to under-utilize preventive care[71][72].

Metrics used in EBM

Diagnosis
Causation
Relative measures
Absolute measures
Health policy
For more information, see: Cost-benefit analysis.
  • Cost per year of life saved[75]
  • Cost of Preventing an Event (COPE)[76]. For example, to prevent a major vascular event n a high-risk adult , the number needed to treat is 19, the number of years of treatment are 5, and the daily cost of the generic drug is 68 cents. The COPE is 19 * 5 * ( 365 * .68) which equals $23,579 in the United States.
  • Years (or months or days) of life saved. "A gain in life expectancy of a month from a preventive intervention targeted at populations at average risk and a gain of a year from a preventive intervention targeted at populations at elevated risk can both be considered large."[77]

Original research studies: levels of evidence

'Levels of evidence' were first proposed in 1979 bye the Canadian Task Force on the Periodic Health Examination[44] then modified by the American College of Chest Physicians[78][79] to create a framework for judging the strength of research. An example of levels of evidence is, based on prior work[45]:

These levels of evidence have been criticized as only representing one of two views of medical science.[81] Vandenbroucke proposes that the two views of medical research are:

  1. Evaluation of interventions. In this view, the randomized controlled trial is most important.
  2. Discovery and explanation. In this view, the randomized controlled trial is not supreme and observational studies, subgroup analyses, and secondary analyses are important.

In practice, randomized controlled trials are available to support only 21%[82] to 53%[83] of principal therapeutic decisions.[84] Due to this, evidence-based medicine has evolved to accept lesser levels of evidence when randomized controlled trials are not available.[85]

The Grade Working Group recognizes that assessing medical evidence involves attention to other dimensions than study design, and expanded upon the levels of evidence in 2004.[86][87] These dimensions include: study design; study quality; consistency of study results; and directness (e.g. how close does the research study mirror clinical practice)

Summarizing the evidence

Assessing a body of research evidence

Several systems have been proposed to assess whether a body of research evidence establishes causality.

Koch's postulates[88]
  • "The bacterium must be present in every case of the disease."
  • "The bacterium must be isolated from the diseased host and grown in pure culture."
  • "The specific disease must be reproduced when a pure culture of the bacterium is inoculated into a healthy susceptible host."
  • "The bacterium must be recoverable from the experimentally infected host."

In the 1880's Koch proposed postulates (Koch's Postulates) that suggest association.[89] However, even though the postulates focus on establishing casuality among infections diseases, examples have emerged that violate his postulates.[88]

Bradford Hill criteria[90]
  • Strength or magnitude of association?
  • Consistency of association across studies?
  • Specificity of association?
  • Temporality of association?
  • Plausibility based on biological knowledge?
  • Biological gradient: or dose-response relationship?
  • Coherence? Does the proposed association explain other observations?
  • Experimental evidence?
  • Analogy?

The Bradford Hill criteria were proposed in 1965 in response to studies of the association between tobacco and lung cancer:[90]

More explicit methods have been proposed by groups such as the U.S. Preventive Services Task Force (USPSTF) (see yellow text box above), the American College of Chest Physicians[78][79] and the Grade Working Group[91] The Grade Working Group combines the quality of research studies with their clinical relevance.[86] For example, this allows comparing a randomized control trial in a population that is not exactly like the population of interest versus a cohort study that is from a relevant population. The concept that there are multiple dimensions in assessing evidence has been expanded to a proposal that assessing evidence is not a linear process, but is circular.[92]

Diamond has proposed a method using Bayesian beliefs for assessing medical evidence that categorizes beliefs similarly to how evidence is assessed in the legal system.[93]

The legal system
See Medical malpractice#Standard of care

Systematic review

For more information, see: Systematic review.

A systematic review is a summary of healthcare research that involves a thorough literature search and critical appraisal of individual studies to identify the valid and applicable evidence. It often, but not always, uses appropriate techniques (meta-analysis) to combine studies, and may grade the quality of the particular pieces of evidence according to the methodology used, and according to strengths or weaknesses of the study design. While many systematic reviews are based on an explicit quantitative meta-analysis of available data, there are also qualitative reviews which nonetheless adhere to the standards for gathering, analyzing and reporting evidence.

Clinical practice guidelines

For more information, see: Clinical practice guideline.

Clinical practice guidelines are defined as "Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery."[94]

Incorporating evidence into clinical care

see also Teaching evidence-based medicine

Medical informatics

For more information, see: Medical informatics.

Practicing clinicians cite the lack of time for keeping up with emerging medical evidence that may change clinical practice.[95] Medical informatics is an essential adjunct to EBM, and focuses on creating tools to access and apply the best evidence for making decisions about patient care.[3] Before practicing EBM, informaticians (or informationists) must be familiar with medical journals, literature databases, medical textbooks, practice guidelines, and the growing number of other evidence-based resources, like the Cochrane Database of Systematic Reviews and Clinical Evidence.[95] Similarly, for practicing medical informatics properly, it is essential to have an understanding of EBM, including the ability to phrase an answerable question, locate and retrieve the best evidence, and critically appraise and apply it.[96][97]

Health care quality assurance

For more information, see: Health care quality assurance.

Criticisms of EBM

Statue of David Hume. "Man is a reasonable being; and as such, receives from science his proper food and nourishment: But so narrow are the bounds of human understanding, that little satisfaction can be hoped for in this particular..." Hume recognised clearly the difficulties in gaining a general understanding merely by accumulating observations.

There are a number of criticisms of EBM.[98][99]

Excessive reliance on empiricism and deduction

EBM has been criticized as an attempt to define knowledge in medicine in the same way that was done unsuccessfully by the logical positivists in epistemology, "trying to establish a secure foundation for scientific knowledge based only on observed facts" [100]and not recognizing the fallible nature of knowledge in general.[101] The problem of relying on empiric evidence as a foundation for knowledge was recognized over 100 years ago and is known as the "Problem of Induction" or "Hume's Problem".[102] Alternative logic is induction and abduction.[103]

Inability to individualize for each patient

A general problem with EBM is that it seeks to make recommendations for treatment that (on balance) are likely to provide the best treatment for most patients. However what is the best treatment for most patients is not necessarily the best treatment for a particular individual patient. The causes of disease, and the patient responses to treatment all vary considerably, and are affected for example by the individual's genetic make-up, their particular history, and by factors of individual lifestyle. To take these properly into account requires the clinical experience of the treating physician, and over-reliance upon recommendations based upon statistical outcomes of treatments given in a standardised way to large populations may not always lead to the best care for a particular individual.

Ulterior motives

An early criticism of EBM is that it will be a guise for rationing resources or other goals that are not in the interest of the patient.[104][105] In 1994, the American Medical Association helped introduce the "Patient Protection Act" in Congress to reduce the power of insurers to use guidelines to deny payment for a medical services.[106] As a possible example, Milliman Care Guidelines state they produce "evidence-based clinical guidelines since 1990".[107] In 2000, an academic pediatrician sued Milliman for using his name as an author on a practice guidelines that he stated were "dangerous" [108][109][110] A similar suit disputing the origin of care decisions at Kaiser has been filed.[111] The outcomes of both suits are not known.

Conversely, clinical practice guidelines by the Infectious Disease Society of America are being investigated by Connecticut's attorney general on grounds that the guidelines, which do not recognize a chronic form of Lyme disease, are anticompetitive.[112][113]

EBM not recognizing the limits of clinical epidemiology

EBM is a set of techniques derived from clinical epidemiology, but a common criticism is that epidemiology can show association but not causation. While clinical epidemiology has its role in inspiring clinical decisions if it is complemented with testable hypotheses on disease,[114] many critics consider that EBM is a form of clinical epidemiology which became so common in health care systems, and imposed such an empiricist bias on medical research, that it has undermined the notion of causal inference in clinical practice.[115] It is argued that it has even become condemnable to use common sense,[116] as was cleverly illustrated in a systematic review of randomized controlled trials studying the effects of parachutes against gravitational challenges (free falls).[117]

Lorenz butterfly showing two attractors in a complex, chaotic system. See complexity science.

Complexity science

For more information, see: complexity science.

Complexity science and chaos theory are proposed as further explaining the nature of medical knowledge[118][119] and education[120].

Footnotes

  1. Sackett DL et al. (1996). "Evidence based medicine: what it is and what it isn't". BMJ 312: 71–2. PMID 8555924[e]
  2. Evidence-Based Medicine Working Group (1992). "Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group". JAMA 268: 2420–5. PMID 1404801[e]
  3. 3.0 3.1 Glasziou, Paul; Strauss, Sharon Y. (2005). Evidence-based medicine: how to practice and teach EBM. Elsevier/Churchill Livingstone. ISBN 0-443-07444-5. 
  4. Thier SL, Yu-Isenberg KS, Leas BF et al (2008). "In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines". Manag Care 17: 48-52, 55-7. PMID 18361259[e]
  5. Manheimer E et al. (2007). "Meta-analysis: acupuncture for osteoarthritis of the knee". Ann Intern Med 146: 868–77. PMID 17577006[e]
  6. Assefi NP et al. (2005). "A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia". Ann Intern Med 143: 10–9. PMID 15998750[e]
  7. Clancy CM, Cronin K (2005). "Evidence-based decision making: global evidence, local decisions". Health Affairs (Project Hope) 24: 151–62. DOI:10.1377/hlthaff.24.1.151. PMID 15647226. Research Blogging.
  8. Shojania KG, Grimshaw JM (2005). "Evidence-based quality improvement: the state of the science". Health Affairs (Project Hope) 24: 138–50. DOI:10.1377/hlthaff.24.1.138. PMID 15647225. Research Blogging.
  9. Fielding JE, Briss PA (2006). "Promoting evidence-based public health policy: can we have better evidence and more action?". Health Affairs (Project Hope) 25: 969–78. DOI:10.1377/hlthaff.25.4.969. PMID 16835176. Research Blogging.
  10. Foote SB, Town RJ (2007). "Implementing evidence-based medicine through medicare coverage decisions". Health Affairs (Project Hope) 26 (6): 1634–42. DOI:10.1377/hlthaff.26.6.1634. PMID 17978383. Research Blogging.
  11. Fox DM (2005). "Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions". Health Affairs (Project Hope) 24: 114–22. DOI:10.1377/hlthaff.24.1.114. PMID 15647221. Research Blogging.
  12. 12.0 12.1 Eddy DM (2005). "Evidence-based medicine: a unified approach". Health Affairs (Project Hope) 24: 9-17. DOI:10.1377/hlthaff.24.1.9. PMID 15647211. Research Blogging.
  13. Aberegg SK, O'Brien JM (2009). "The normalization heuristic: an untested hypothesis that may misguide medical decisions.". Med Hypotheses 72 (6): 745-8. DOI:10.1016/j.mehy.2008.10.030. PMID 19231086. Research Blogging.
  14. McDonald CJ (1996). "Medical heuristics: the silent adjudicators of clinical practice.". Ann Intern Med 124 (1 Pt 1): 56-62. PMID 7503478.
  15. 15.0 15.1 Haynes RB (2006). "Of studies, syntheses, synopses, summaries, and systems: the "5S" evolution of information services for evidence-based health care decisions". ACP J Club 145: A8. PMID 17080967[e]
  16. Richardson WS, Wilson MC, Nishikawa J, Hayward RS (1995 Nov-Dec). "The well-built clinical question: a key to evidence-based decisions.". ACP J Club 123 (3): A12-3. PMID 7582737.
  17. Huang X, Lin J, Demner-Fushman D (2006). "Evaluation of PICO as a knowledge representation for clinical questions". AMIA Annu Symp Proc: 359–63. PMID 17238363. PMC 1839740[e]
  18. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P (2007). "Utilization of the PICO framework to improve searching PubMed for clinical questions". BMC Med Inform Decis Mak 7: 16. DOI:10.1186/1472-6947-7-16. PMID 17573961. PMC 1904193. Research Blogging.
  19. 19.0 19.1 19.2 Ioannidis JP (2005). "Contradicted and initially stronger effects in highly cited clinical research.". JAMA 294 (2): 218-28. DOI:10.1001/jama.294.2.218. PMID 16014596. Research Blogging.
  20. 20.0 20.1 Poynard T, Munteanu M, Ratziu V, Benhamou Y, Di Martino V, Taieb J et al. (2002). "Truth survival in clinical research: an evidence-based requiem?". Ann Intern Med 136 (12): 888-95. PMID 12069563.
  21. 21.0 21.1 Hall JC, Platell C (1997). "Half-life of truth in surgical literature.". Lancet 350 (9093): 1752. DOI:10.1016/S0140-6736(05)63577-5. PMID 9413475. Research Blogging.
  22. 22.0 22.1 Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D (2007). "How quickly do systematic reviews go out of date? A survival analysis.". Ann Intern Med 147 (4): 224-33. PMID 17638714.
  23. 23.0 23.1 Shekelle PG, Ortiz E, Rhodes S, Morton SC, Eccles MP, Grimshaw JM et al. (2001). "Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated?". JAMA 286 (12): 1461-7. PMID 11572738.
  24. 24.0 24.1 24.2 Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH (2002). "Timing of new black box warnings and withdrawals for prescription medications.". JAMA 287 (17): 2215-20. PMID 11980521.
  25. Banks DE et al. (2007). "Decreased hospital length of stay associated with presentation of cases at morning report with librarian support". JMLA 95: 381–7. DOI:10.3163/1536-5050.95.4.381. PMID 17971885. Research Blogging.
  26. Lucas BP, Evans AT, Reilly BM, et al (2004). "The impact of evidence on physicians' inpatient treatment decisions". J Gen Intern Med 19 (5 Pt 1): 402–9. DOI:10.1111/j.1525-1497.2004.30306.x. PMID 15109337. Research Blogging.
  27. Rosenbloom ST, Giuse NB, Jerome RN, Blackford JU (January 2005). "Providing evidence-based answers to complex clinical questions: evaluating the consistency of article selection". Acad Med 80 (1): 109–14. PMID 15618105[e]
  28. 28.0 28.1 McKibbon KA, Fridsma DB (2006). "Effectiveness of clinician-selected electronic information resources for answering primary care physicians' information needs". JAMIA 13: 653–9. DOI:10.1197/jamia.M2087. PMID 16929042. Research Blogging.
  29. Westbrook JI, Coiera EW, Gosling AS (2005). "Do online information retrieval systems help experienced clinicians answer clinical questions?". J Am Med Inform Assoc 12 (3): 315–21. DOI:10.1197/jamia.M1717. PMID 15684126. Research Blogging.
  30. DiCenso A, Bayley L, Haynes RB (2009). "ACP Journal Club. Editorial: Accessing preappraised evidence: fine-tuning the 5S model into a 6S model.". Ann Intern Med 151 (6): JC3-2, JC3-3. PMID 19755349. Full text from www.acpjc.org
  31. Patel MR et al. (2006). "Randomized trial for answers to clinical questions: evaluating a pre-appraised versus a MEDLINE search protocol". JMLA 94: 382–7. PMID 17082828[e]
  32. U.S. Preventive Services Task Force Ratings: [Strength of Recommendations and Quality of Evidence. Guide to Clinical Preventive Services, Third Edition: Periodic Updates, 2000-2003. Hosted by Agency for Healthcare Research and Quality, Rockville, MD.
  33. Ioannidis JP et al. (1998). "Issues in comparisons between meta-analyses and large trials". JAMA 279: 1089–93. PMID 9546568[e]
  34. 34.0 34.1 Dickersin K et al. (1992). "Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards". JAMA 267: 374–8. PMID 1727960[e]
  35. Smith R (2005). "Medical journals are an extension of the marketing arm of pharmaceutical companies". PLoS Med 2: e138. DOI:10.1371/journal.pmed.0020138. PMID 15916457. Research Blogging.
  36. Melander H et al. (2003). "Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications". BMJ 326: 1171–3. DOI:10.1136/bmj.326.7400.1171. PMID 12775615. Research Blogging.
  37. Saint S et al (2000). "Journal reading habits of internists". J Gen Intern Med 15: 881–4. PMID 11119185[e]
  38. Pitkin RM et al. (1999). "Accuracy of data in abstracts of published research articles". JAMA 281: 1110–1. PMID 10188662[e]
  39. Lord, Charles, Ross, Lee, and Lepper, Mark (1979). 'Biased Assimilation and Attitude Polarization: The Effects of Prior Theories on Subsequently Considered Evidence',Journal of Personality and Social Psychology, 37 (11): 2098-2109.
  40. Bergman DA, Pantell RH (May 1986). "The impact of reading a clinical study on treatment decisions of physicians and residents". J Med Educ 61 (5): 380–6. PMID 3701813[e]
  41. (1981) "How to read clinical journals: I. why to read them and how to start reading them critically.". Can Med Assoc J 124 (5): 555-8. PMID 7471000. PMC PMC1705173[e]
  42. Hayward RA, Kent DM, Vijan S, Hofer TP (2006). "Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis.". BMC Med Res Methodol 6: 18. DOI:10.1186/1471-2288-6-18. PMID 16613605. PMC PMC1523355. Research Blogging.
  43. Lin JW, Chang CH, Lin MW, Ebell MH, Chiang JH (2011). "Automating the process of critical appraisal and assessing the strength of evidence with information extraction technology.". J Eval Clin Pract. DOI:10.1111/j.1365-2753.2011.01712.x. PMID 21707873. Research Blogging.
  44. 44.0 44.1 (1979) "The periodic health examination. Canadian Task Force on the Periodic Health Examination.". Can Med Assoc J 121 (9): 1193-254. PMID 115569. PMC PMC1704686.
  45. 45.0 45.1 Levels of Evidence. Retrieved on 2007-12-31.
  46. National Library of Medicine. Publication bias. Retrieved on 2007-12-17.
  47. Glasziou P, Doll H (2007). "Was the study big enough? Two "café" rules (Editorial)". ACP J Club 147: A08. PMID 17975858[e]
  48. Montori VM et al (November 2005). "Randomized trials stopped early for benefit: a systematic review". JAMA 294: 2203–9. DOI:10.1001/jama.294.17.2203. PMID 16264162. Research Blogging.
  49. Trotta, F et al. (2008) Stopping a trial early in oncology: for patients or for industry? Ann Oncol mdn042. http://dx.doi.org/10.1093/annonc/mdn042
  50. Slutsky AS, Lavery JV (2004). "Data Safety and Monitoring Boards". N Engl J Med 350: 1143–7. DOI:10.1056/NEJMsb033476. PMID 15014189. Research Blogging.
  51. 51.0 51.1 Goodman SN (1999). "Toward evidence-based medical statistics. 1: The P value fallacy". Ann Intern Med 130: 995–1004. PMID 10383371[e]
  52. Browner WS, Newman TB (1987). "Are all significant P values created equal? The analogy between diagnostic tests and clinical research". JAMA 257: 2459–63. PMID 3573245[e]
  53. Goodman SN (1999). "Toward evidence-based medical statistics. 2: The Bayes factor". Ann Intern Med 130: 1005–13. PMID 10383350[e]
  54. Ancker JS, Kaufman D (2007). "Rethinking health numeracy: a multidisciplinary literature review". DOI:10.1197/jamia.M2464. PMID 17712082. Research Blogging.
  55. Dubeau CE et al. (1986). "Premature conclusions in the diagnosis of iron-deficiency anemia: cause and effect". Med Decis Making 6: 169–73. PMID 3736379[e]
  56. Coderre S et al. (2003). "Diagnostic reasoning strategies and diagnostic success". Med Educ 37: 695–703. PMID 12895249[e]
  57. 57.0 57.1 Eddy DM, Clanton CH (1982). "The art of diagnosis: solving the clinicopathological exercise". N Engl J Med 306: 1263–8. PMID 7070446[e]
  58. Gross CP et al. (2000). "Relation between prepublication release of clinical trial results and the practice of carotid endarterectomy". JAMA 284: 2886–93. PMID 11147985[e]
  59. Juurlink DN et al. (2004). "Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study". N Engl J Med 351: 543–51. DOI:10.1056/NEJMoa040135. PMID 15295047. Research Blogging.
  60. Beohar N et al. (2007). "Outcomes and complications associated with off-label and untested use of drug-eluting stents". JAMA 297: 1992–2000. DOI:10.1001/jama.297.18.1992. PMID 17488964. Research Blogging.
  61. Soumerai SB et al. (1997). "Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction". JAMA 277: 115–21. PMID 8990335[e]
  62. Hemingway H et al. (2001). "Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization". N Engl J Med 344: 645–54. PMID 11228280[e]
  63. Turner BJ, Laine C (2001). "Differences between generalists and specialists: knowledge, realism, or primum non nocere?". J Gen Intern Med 16: 422-4. DOI:10.1046/j.1525-1497.2001.016006422.x. PMID 11422641. Research Blogging. PubMed Central
  64. Rawson N et al. (2005). "Factors associated with celecoxib and rofecoxib utilization". Ann Pharmacother 39: 597-602. PMID 15755796.
  65. 65.0 65.1 De Smet BD et al. (2006). "Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited". J Gen Intern Med 21: 694-7. DOI:10.1111/j.1525-1497.2006.00463.x. PMID 16808768. Research Blogging.
  66. Carey T et al. (1995). "The outcomes and costs of care for acute low back pain among patients seen by primary care practitioners, chiropractors, and orthopedic surgeons. The North Carolina Back Pain Project". N Engl J Med 333: 913-7. PMID 7666878.
  67. McKibbon KA et al. (2007). "Which journals do primary care physicians and specialists access from an online service?". JMLA 95: 246-54. DOI:10.3163/1536-5050.95.3.246. PMID 17641754. Research Blogging.
  68. Tatsioni A, Bonitsis NG, Ioannidis JPA (2007) Persistence of contradicted claims in the literature. JAMA 298
  69. Majumdar S et al. (2001). "Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction". J Gen Intern Med 16: 351-9. PMID 11422631.
  70. Fendrick A et al. (1996). "Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease". Am J Gastroenterol 91: 1544-8. PMID 8759658.
  71. Lewis C et al. (1991). "The counseling practices of internists". Ann Intern Med 114: 54-8. PMID 1983933.
  72. Turner B et al.. "Breast cancer screening: effect of physician specialty, practice setting, year of medical school graduation, and sex". Am J Prev Med 8: 78-85. PMID 1599724.
  73. Laupacis A et al. (1988). "An assessment of clinically useful measures of the consequences of treatment". N Engl J Med 318: 1728–33. PMID 3374545[e]
  74. Rembold CM (1998). "Number needed to screen: development of a statistic for disease screening". BMJ 317: 307–12. PMID 9685274[e]
  75. Tengs TO et al (1995). "Five-hundred life-saving interventions and their cost-effectiveness". Risk Anal 15: 369–90. PMID 7604170[e]
  76. Maharaj R (2008). "Adding cost to NNT: the COPE statistic". ACP J. Club 148: A8. PMID 18170986[e]
  77. Wright JC, Weinstein MC (1998). "Gains in life expectancy from medical interventions--standardizing data on outcomes". N Engl J Med 339: 380–6. PMID 9691106[e]
  78. 78.0 78.1 Sackett DL (1989). "Rules of evidence and clinical recommendations on the use of antithrombotic agents.". Chest 95 (2 Suppl): 2S-4S. PMID 2914516.
  79. 79.0 79.1 Sackett DL (1986). "Rules of evidence and clinical recommendations on the use of antithrombotic agents". Chest 89: 2S–3S. PMID 3943408[e]
  80. Sethi NK, Sethi PK (2008). "Evidence-based medicine vs medicine-based evidence". Ann. Neurol.. DOI:10.1002/ana.21354. PMID 18350575. Research Blogging.
  81. Vandenbroucke, JP (2008-03-01). "Observational research, randomised trials, and two views of medical science". PLoS Medicine 5 (3): e67 EP -. DOI:10.1371/journal.pmed.0050067. Retrieved on 2008-03-11. Research Blogging.
  82. Michaud G et al. (1998). "Are therapeutic decisions supported by evidence from health care research?". Arch Intern Med 158: 1665–8. PMID 9701101[e]
  83. Ellis J et al. (1995). "Inpatient general medicine is evidence based. A-Team, Nuffield Department of Clinical Medicine". Lancet 346: 407–10. PMID 7623571[e]
  84. Booth A. Percentage of practice that is evidence based?. Retrieved on 2007-11-15.
  85. Haynes RB (2006). "Of studies, syntheses, synopses, summaries, and systems: the "5S" evolution of information services for evidence-based healthcare decisions". Evidence-based Medicine 11: 162–4. DOI:10.1136/ebm.11.6.162-a. PMID 17213159. Research Blogging.
  86. 86.0 86.1 Atkins D et al (2004). "Grading quality of evidence and strength of recommendations". BMJ 328: 1490. DOI:10.1136/bmj.328.7454.1490. PMID 15205295. Research Blogging.
  87. Guyatt G, et al. (2006). "An emerging consensus on grading recommendations?". ACP J Club 144: A8–9. PMID 16388549[e]
  88. 88.0 88.1 Hopayian K (2004). "Why medicine still needs a scientific foundation: restating the hypotheticodeductive model - part two.". Br J Gen Pract 54 (502): 402-3; discussion 404-5. PMID 15372724. PMC PMC1266186.
  89. Kaufmann SH (December 2005). "Robert Koch, the Nobel Prize, and the ongoing threat of tuberculosis". N. Engl. J. Med. 353 (23): 2423–6. DOI:10.1056/NEJMp058131. PMID 16339091. Research Blogging.
  90. 90.0 90.1 Hill AB (May 1965). "The Environment And Disease: Association Or Causation?". Proc. R. Soc. Med. 58: 295–300. PMID 14283879. PMC 1898525[e]
  91. GRADE working group. Retrieved on 2007-11-23.
  92. Walach H et al. (2006). "Circular instead of hierarchical: methodological principles for the evaluation of complex interventions". BMC Med Res Methodol 6: 29. DOI:10.1186/1471-2288-6-29. PMID 16796762. Research Blogging.
  93. Diamond GA, Kaul S (2009). "Bayesian classification of clinical practice guidelines.". Arch Intern Med 169 (15): 1431-5. DOI:10.1001/archinternmed.2009.235. PMID 19667308. Research Blogging.
  94. National Library of Medicine. Clinical practice guidelines. Retrieved on 2007-10-19.
  95. 95.0 95.1 Mendelson D, Carino TV (2005). "Evidence-based medicine in the United States--de rigueur or dream deferred?". Health Affairs (Project Hope) 24: 133–6. DOI:10.1377/hlthaff.24.1.133. PMID 15647224. Research Blogging.
  96. Hersh W (2002). "Medical informatics education: an alternative pathway for training informationists". JMLA 90: 76–9. PMID 11838463[e]
  97. Shearer BS et al. (2002). "Bringing the best of medical librarianship to the patient team". JMLA 90: 22–31. PMID 11838456[e]
  98. Straus S et al. (2007). "Misunderstandings, misperceptions, and mistakes". Evidence-based medicine 12: 2–3. DOI:10.1136/ebm.12.1.2-a. PMID 17264255. Research Blogging.
  99. Straus SE, McAlister FA (2000). "Evidence-based medicine: a commentary on common criticisms". CMAJ 163: 837–41. PMID 11033714[e]
  100. Goodman SN (2002). "The mammography dilemma: a crisis for evidence-based medicine?". Ann Intern Med 137: 363–5. PMID 12204023[e]
  101. Upshur RE (2000). "Seven characteristics of medical evidence". J Eval Clin Pract 6: 93–7. PMID 10970003[e]
  102. Vickers, J (2006). The Problem of Induction (Stanford Encyclopedia of Philosophy). Stanford Encyclopedia of Philosophy. Retrieved on 2007-11-16.
  103. Rapezzi C, Ferrari R, Branzi A (2005). "White coats and fingerprints: diagnostic reasoning in medicine and investigative methods of fictional detectives.". BMJ 331 (7531): 1491-4. DOI:10.1136/bmj.331.7531.1491. PMID 16373725. PMC PMC1322237. Research Blogging.
  104. Grahame-Smith D (1995). "Evidence based medicine: Socratic dissent". BMJ 310: 1126–7. PMID 7742683[e]
  105. Formoso G et al. (2001). "Practice guidelines: useful and "participative" method? Survey of Italian physicians by professional setting". Arch Intern Med 161: 2037–42. PMID 11525707[e]
  106. Pear, R. A.M.A. and Insurers Clash Over Restrictions on Doctors - New York Times. Retrieved on 2007-11-14.
  107. Evidence-Based Clinical Guidelines by Milliman Care Guidelines. Retrieved on 2007-11-14.
  108. Nissimov, R (2000). Cost-cutting guide used by HMOs called `dangerous' / Doctor on UT-Houston Medical School staff sues publisher. Houston Chronicle. Retrieved on 2007-11-14.
  109. Nissimov, R (2000). Judge tells firm to explain how pediatric rules derived. Houston Chronicle. Retrieved on 2007-11-14.
  110. Martinez, B (2000). Insurance Health-Care Guidelines Are Assailed for Putting Patients Last. Wall Street Journal.
  111. Colliver, V (1/07/2002). Lawsuit disputes truth of Kaiser Permanente ads. San Francisco Chronicle. Retrieved on 2007-11-14.
  112. Warner, S (2/7/2007). The Scientist : State official subpoenas infectious disease group. Retrieved on 2007-11-14.
  113. Gesensway, D (2007). ACP Observer, January-February 2007 - Experts spar over treatment for 'chronic' Lyme disease. Retrieved on 2007-11-14.
  114. Djulbegovic B et al. (2000). "Evidentiary challenges to evidence-based medicine". Journal of evaluation in clinical practice 6: 99–109. PMID 10970004[e]
  115. Charlton BG. [Book Review: Evidence-based medicine: how to practice and teach EBM by Sackett DL, Richardson WS, Rosenberg W, Haynes RB. http://www.hedweb.com/bgcharlton/journalism/ebm.html] Journal of Evaluation in Clinical Practice. 1997; 3:169-172
  116. Michelson J (2004). "Critique of (im)pure reason: evidence-based medicine and common sense". J Evaluation Clin Pract 10: 157–61. DOI:10.1111/j.1365-2753.2003.00478.x. PMID 15189382. Research Blogging.
  117. Smith GC, Pell JP (2003). "Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials". BMJ 327: 1459–61. DOI:10.1136/bmj.327.7429.1459. PMID 14684649. Research Blogging.
  118. Sweeney, Kieran (2006). Complexity in Primary Care: Understanding Its Value. Abingdon: Radcliffe Medical Press. ISBN 1-85775-724-6. Book review
  119. Holt, Tim A (2004). Complexity for Clinicians. Abingdon: Radcliffe Medical Press. ISBN 1-85775-855-2.  Book review, ACP Journal Club Review
  120. Fraser SW, Greenhalgh T (2001). "Coping with complexity: educating for capability". BMJ 323 (7316): 799–803. PMID 11588088[e]